Clinical Trials

Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

Condition:   Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia
Interventions:   Drug: Azacytidine, HAG Regimen;   Drug: Azacytidine
Sponsor:   Shenzhen Second People's Hospital
Recruiting

Wed, 13 Mar 2019 12:00:00 EDT

A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders

Conditions:   MDS;   Systemic Autoimmune Diseases
Intervention:   Drug: Azacitidine
Sponsors:   Groupe Francophone des Myelodysplasies;   Celgene
Active, not recruiting

Wed, 07 Dec 2016 12:00:00 EST

A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC

Condition:   Myelodysplastic Syndromes,Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine combined HHT;   Drug: Azacitidine regimen
Sponsor:   Shandong Provincial Hospital
Recruiting

Fri, 07 Jun 2019 12:00:00 EDT

Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation

Condition:   Recurrent IDH1/2 Mutated Glioma
Intervention:   Drug: Azacitidine
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting

Wed, 12 Sep 2018 12:00:00 EDT

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Conditions:   Myelodysplastic Syndrome With Gene Mutation;   Acute Myeloid Leukemia With Gene Mutations;   Myeloproliferative Neoplasm;   Chronic Myelomonocytic Leukemia
Interventions:   Drug: APR-246;   Drug: Azacitidine
Sponsors:   Groupe Francophone des Myelodysplasies;   Aprea Therapeutics
Active, not recruiting

Tue, 17 Jul 2018 12:00:00 EDT

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients

Condition:   MDS
Intervention:   Drug: Azacitidine and LDE255
Sponsors:   Groupe Francophone des Myelodysplasies;   Novartis
Completed

Tue, 23 Dec 2014 12:00:00 EST

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

Conditions:   Chronic Myeloid Leukemia;   Myelofibroses
Interventions:   Drug: Azacitidine;   Drug: Selumetinib
Sponsor:   University of Chicago
Recruiting

Tue, 31 Oct 2017 12:00:00 EDT

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome (MDS)
Intervention:   Drug: Azacitidine
Sponsor:   Celgene
Completed

Wed, 16 May 2012 12:00:00 EDT

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)

Conditions:   Acute Myelocytic Leukemia;   Myelodysplastic Syndrome
Intervention:   Drug: Azacitidine
Sponsor:   Technische Universität Dresden
Unknown status

Mon, 31 Oct 2011 12:00:00 EDT

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer

Conditions:   Breast Cancer Female;   Breast Cancer Invasive
Intervention:   Drug: Azacitidine
Sponsor:   University of Illinois at Chicago
Recruiting

Tue, 18 May 2021 12:00:00 EDT

Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer

Conditions:   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck
Intervention:   Drug: Azacitidine and Cisplatin
Sponsor:   Loma Linda University
Terminated

Thu, 14 May 2009 12:00:00 EDT

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Conditions:   Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Juvenile
Intervention:   Drug: Azacitidine
Sponsor:   Celgene
Completed

Tue, 19 May 2015 12:00:00 EDT

Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: HMPL-523;   Drug: Azacitidine
Sponsor:   Hutchison Medipharma Limited
Terminated

Fri, 30 Mar 2018 12:00:00 EDT

Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: Azacitidine and Venetoclax
Sponsor:   University of Colorado, Denver
Active, not recruiting

Thu, 15 Mar 2018 12:00:00 EDT

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

Conditions:   Acute Myelogenous Leukemia;   Acute Lymphoid Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: azacitidine;   Biological: donor lymphocyte infusion
Sponsors:   University of California, San Francisco;   Hellman Foundation
Completed

Mon, 01 Jun 2015 12:00:00 EDT

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma

Condition:   Brain Tumor Recurrent
Intervention:   Drug: 5-Azacytidine
Sponsor:   The University of Texas Health Science Center, Houston
Completed

Fri, 21 Oct 2016 12:00:00 EDT

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Conditions:   Myelodysplastic Syndromes;   MDS/MPN Crossover Syndromes
Interventions:   Drug: 5-azacytidine;   Drug: Decitabine
Sponsor:   Benjamin Tomlinson
Recruiting

Thu, 05 Dec 2019 12:00:00 EST

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Ceplene®, IL-2, Azacitidine;   Drug: Azacitidine
Sponsors:   Groupe Francophone des Myelodysplasies;   EpiCept Corporation
Withdrawn

Tue, 29 Mar 2011 12:00:00 EDT

Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Deferasirox + Azacitidine;   Drug: Azacitidine
Sponsors:   Sunnybrook Health Sciences Centre;   Novartis
Terminated

Fri, 17 Jan 2014 12:00:00 EST

5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: Azacitidine
Sponsors:   Seoul St. Mary's Hospital;   Celgene Corporation
Unknown status

Mon, 30 Jul 2012 12:00:00 EDT

A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia

Conditions:   Myelodysplastic Syndromes (MDS);   Acute Myeloid Leukaemia (AML)
Intervention:   Drug: Azacitidine and eltrombopag
Sponsors:   Peter MacCallum Cancer Centre, Australia;   GlaxoSmithKline;   Celgene Corporation
Completed

Thu, 08 Dec 2011 12:00:00 EST

Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS

Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Intervention:   Drug: 5-azacytidine (5-aza) maintenance therapy after transplant
Sponsor:   University of Pittsburgh
Withdrawn

Wed, 30 Jul 2014 12:00:00 EDT

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: Cusatuzumab;   Drug: Azacitidine
Sponsors:   Janssen Pharmaceutical K.K.;   argenx
Completed

Mon, 27 Jan 2020 12:00:00 EST

Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

Conditions:   Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Intervention:   Drug: 5-Azacitidine
Sponsor:   Heinrich-Heine University, Duesseldorf
Completed

Fri, 21 Nov 2008 12:00:00 EST

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions:   Biological: Donor lymphocyte infusion;   Drug: Azacytidine
Sponsors:   Carlos Graux, MD, PhD;   Celgene Corporation;   Belgian Hematological Society
Completed

Fri, 20 Dec 2013 12:00:00 EST

TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid

Conditions:   Myelodysplastic Syndromes;   Myeloproliferative Neoplasm;   Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Ascorbic acid
Sponsor:   Case Comprehensive Cancer Center
Completed

Thu, 11 Jan 2018 12:00:00 EST

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Condition:   Higher Risk Myelodysplastic Syndromes
Interventions:   Drug: evorpacept;   Drug: azacitidine
Sponsor:   ALX Oncology Inc.
Recruiting

Thu, 04 Jun 2020 12:00:00 EDT

Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy

Condition:   Leukemia
Intervention:   Drug: Azacitidine
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Celgene Corporation
Completed

Fri, 13 Oct 2006 12:00:00 EDT

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: Azacitidine
Sponsor:   Groupe Francophone des Myelodysplasies
Completed

Mon, 28 Feb 2011 12:00:00 EST

A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

Condition:   MDS
Intervention:   Drug: Lenalidomide and azacitidine combination
Sponsors:   Rush University Medical Center;   Celgene Corporation
Terminated

Thu, 23 Jun 2011 12:00:00 EDT

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Conditions:   Myelodysplastic Syndrome;   Acute Myelogenous Leukemia
Interventions:   Drug: Azacitidine;   Drug: azacitidine + lenalidomide
Sponsor:   Nordic MDS Group
Unknown status

Fri, 16 Mar 2012 12:00:00 EDT

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: DCLL9718S;   Drug: Azacitidine
Sponsor:   Genentech, Inc.
Completed

Mon, 02 Oct 2017 12:00:00 EDT

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

Conditions:   Myelodysplastic Syndrome;   Leukemia
Intervention:   Drug: Azacitidine
Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
Completed

Tue, 11 Jul 2006 12:00:00 EDT

Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma

Condition:   Non-hodgkin Lymphoma,B Cell
Intervention:   Drug: Azacytidine, Bendamustine and Piamprizumab
Sponsor:   Chinese PLA General Hospital
Recruiting

Fri, 21 May 2021 12:00:00 EDT

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

Conditions:   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Interventions:   Drug: oral rigosertib;   Drug: Azacitidine
Sponsor:   Onconova Therapeutics, Inc.
Completed

Wed, 21 Aug 2013 12:00:00 EDT

Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes

Condition:   High Grade Myelodysplastic Syndrome Lesions
Intervention:   Drug: azacitidine and idarubicin
Sponsor:   Groupe Francophone des Myelodysplasies
Completed

Mon, 28 Feb 2011 12:00:00 EST

SY-1425 Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: SY-1425 + Azacitidine;   Drug: SY-1425 Matched Placebo + Azacitidine
Sponsor:   Syros Pharmaceuticals
Recruiting

Mon, 15 Mar 2021 12:00:00 EDT

A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma

Conditions:   Solid Tumors;   Virally Mediated Cancers and Liposarcoma
Intervention:   Drug: oral 5-azacitidine in combination with romidepsin
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Celgene Corporation
Completed

Thu, 23 Feb 2012 12:00:00 EST

Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy

Condition:   Leukemia
Intervention:   Drug: azacytidine
Sponsor:   Swiss Group for Clinical Cancer Research
Completed

Thu, 21 Aug 2008 12:00:00 EDT

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: Azacitidine
Sponsor:   Washington University School of Medicine
Completed

Fri, 06 Oct 2006 12:00:00 EDT

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: Mocetinostat;   Drug: Azacitidine
Sponsor:   Mirati Therapeutics Inc.
Completed

Mon, 23 Dec 2013 12:00:00 EST

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

Conditions:   Leukemia;   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes (MDS)
Interventions:   Drug: Azacitidine;   Drug: Lenalidomide
Sponsors:   Stanford University;   Celgene Corporation
Terminated

Wed, 28 Sep 2011 12:00:00 EDT

Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Venetoclax
Sponsor:   University of Colorado, Denver
Recruiting

Thu, 28 Jun 2018 12:00:00 EDT

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Condition:   Myeloid Malignancy
Intervention:   Drug: azacitidine
Sponsor:   Henry Ford Health System
Recruiting

Thu, 21 Feb 2019 12:00:00 EST

5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: Azacytidine
Sponsors:   Università degli Studi di Brescia;   University of Udine;   University of Bologna;   University of Genova;   University of Siena;   Cremona;   Mantova
Completed

Tue, 12 May 2009 12:00:00 EDT

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: S65487 and azacitidine
Sponsors:   Institut de Recherches Internationales Servier;   ADIR, a Servier Group company
Recruiting

Fri, 05 Feb 2021 12:00:00 EST

Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

Conditions:   Acute Myeloid Leukemia;   Myelodysplasia
Interventions:   Drug: Oral azacitidine;   Drug: Matched placebo
Sponsor:   University of Birmingham
Recruiting

Fri, 22 Nov 2019 12:00:00 EST

Ph II Study of Azacitidine in Myelofibrosis

Condition:   Myelofibrosis
Intervention:   Drug: Azacitidine
Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
Completed

Fri, 07 Dec 2007 12:00:00 EST

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Conditions:   Myelodysplastic Syndromes;   Myeloproliferative Neoplasms;   Myelofibrosis
Interventions:   Drug: Jaktinib;   Drug: azacitidine
Sponsor:   Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Not yet recruiting

Thu, 29 Apr 2021 12:00:00 EDT

An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: Azacitidine
Sponsor:   Celgene
Completed

Mon, 23 Aug 2010 12:00:00 EDT

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: 5-azacytidine
Sponsors:   Virginia Commonwealth University;   Celgene Corporation
Completed

Thu, 24 Jul 2008 12:00:00 EDT

Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: Azacitidine;   Drug: Vorinostat
Sponsors:   University of Birmingham;   Leukemia Research Fund;   Celgene;   Merck Sharp & Dohme Corp.
Completed

Tue, 12 Jun 2012 12:00:00 EDT

Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML

Conditions:   Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Interventions:   Biological: NPMW-peptide vaccine;   Drug: Azacitidine
Sponsors:   Daniel El Fassi;   Technical University of Denmark
Completed

Tue, 26 Apr 2016 12:00:00 EDT

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Condition:   Leukemia
Interventions:   Drug: Azacytidine;   Drug: GM-CSF
Sponsor:   M.D. Anderson Cancer Center
Terminated

Fri, 02 Mar 2012 12:00:00 EST

Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Homoharringtonine;   Drug: Azacitidine
Sponsor:   Ge Zheng
Recruiting

Thu, 30 Jan 2020 12:00:00 EST

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Secondary Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Ibrutinib
Sponsors:   Brian Jonas;   Pharmacyclics LLC.
Active, not recruiting

Fri, 18 Sep 2015 12:00:00 EDT

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Lymphoma;   Multiple Myeloma;   Leukemia, Myelomonocytic, Chronic
Intervention:   Drug: azacitidine
Sponsor:   Celgene
Completed

Mon, 29 Sep 2008 12:00:00 EDT

Efficacy and Safety Evaluation of IBI188 in Combination With Azacitidine in Treatment of Patients With Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: IBI188;   Drug: Azacitidine
Sponsor:   Innovent Biologics (Suzhou) Co. Ltd.
Recruiting

Fri, 24 Jul 2020 12:00:00 EDT

A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

Condition:   MDS
Interventions:   Drug: IBI188;   Drug: Azacitidine
Sponsor:   Innovent Biologics (Suzhou) Co. Ltd.
Suspended

Thu, 13 Aug 2020 12:00:00 EDT

Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Condition:   Large B-Cell Diffuse Lymphoma
Interventions:   Drug: Oral azacitidine;   Drug: R-ICE
Sponsors:   Medical University of South Carolina;   Celgene Corporation
Recruiting

Thu, 01 Mar 2018 12:00:00 EST

Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
Interventions:   Drug: Vosaroxin;   Drug: Azacitidine
Sponsors:   University of Ulm;   Sunesis Pharmaceuticals
Completed

Thu, 09 Nov 2017 12:00:00 EST

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)
Sponsors:   James J Lee;   Incyte Corporation;   Merck Sharp & Dohme Corp.
Withdrawn

Fri, 09 Jun 2017 12:00:00 EDT

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: Azacitidine;   Drug: Cusatuzumab
Sponsors:   Janssen Research & Development, LLC;   argenx
Active, not recruiting

Wed, 17 Jul 2019 12:00:00 EDT

Safety and Efficacy of IBI188 With Azacitidine in Newly Diagnosed Higher Risk MDS

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: IBI188+azacitidine;   Drug: Drug:Azacitidine
Sponsor:   Innovent Biologics (Suzhou) Co. Ltd.
Recruiting

Fri, 24 Jul 2020 12:00:00 EDT

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Conditions:   Chronic Myelomonocytic Leukemia-0;   Chronic Myelomonocytic Leukemia-1;   Chronic Myelomonocytic Leukemia-2;   Myelodysplastic Syndrome;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Seclidemstat
Sponsor:   M.D. Anderson Cancer Center
Recruiting

Tue, 02 Feb 2021 12:00:00 EST

Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

Conditions:   Leukemia;   AML;   MDS
Intervention:   Drug: Azacitidine
Sponsors:   M.D. Anderson Cancer Center;   Celgene
Completed

Thu, 23 Apr 2009 12:00:00 EDT

Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Dasatinib
Sponsors:   LanZhou University;   Beijing Health Alliance Charitable Foundation
Recruiting

Mon, 13 Sep 2021 12:00:00 EDT

Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy

Conditions:   Acute Myeloid Leukemia;   Elderly
Intervention:   Drug: Azacitidine
Sponsor:   Kansas City Veteran Affairs Medical Center
Unknown status

Wed, 06 Aug 2008 12:00:00 EDT

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Condition:   MDS
Interventions:   Drug: APR-246 + azacitidine;   Drug: Azacitidine
Sponsor:   Aprea Therapeutics
Active, not recruiting

Mon, 19 Nov 2018 12:00:00 EST

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: Pevonedistat;   Drug: Azacitidine
Sponsors:   PETHEMA Foundation;   Millennium Pharmaceuticals, Inc.;   Dynamic Science S.L.
Recruiting

Mon, 16 Sep 2019 12:00:00 EDT

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic
Interventions:   Drug: Azacitidine;   Drug: Cusatuzumab
Sponsors:   Janssen Research & Development, LLC;   argenx
Withdrawn

Tue, 11 Feb 2020 12:00:00 EST

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia

Condition:   Myelodysplastic Syndrome (MDS)
Intervention:   Drug: Azacitidine
Sponsor:   Asociación Andaluza de Hematología y Hemoterapia
Completed

Tue, 19 Apr 2011 12:00:00 EDT

Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: vosaroxin;   Drug: Azacitidine
Sponsors:   Washington University School of Medicine;   Sunesis Pharmaceuticals
Active, not recruiting

Thu, 01 Aug 2013 12:00:00 EDT

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

Conditions:   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Myelodysplastic Syndrome;   Recurrent Myeloproliferative Neoplasm
Interventions:   Drug: Azacitidine;   Drug: Quizartinib
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Thu, 30 Jul 2020 12:00:00 EDT

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Conditions:   Chronic Lymphocytic Leukemia;   Leukemia
Intervention:   Drug: 5-Azacytidine
Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
Terminated

Tue, 19 Dec 2006 12:00:00 EST

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Conditions:   AML;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   CMML;   Myelodysplastic Syndromes;   High-risk Myelodysplastic Syndrome;   MDS
Interventions:   Drug: APG-115;   Drug: 5-azacitidine
Sponsor:   Ascentage Pharma Group Inc.
Recruiting

Fri, 24 Apr 2020 12:00:00 EDT

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Condition:   Acute Myeloid Leukemia or Myelodysplastic Syndromes
Intervention:   Drug: APR-246
Sponsor:   Aprea Therapeutics
Active, not recruiting

Tue, 30 Apr 2019 12:00:00 EDT

VENETOCLAX AND AZACITIDINE FOR THE MANAGEMENT OF MOLECULAR RELAPSE/PROGRESSION IN ADULT NPM1-MUTATED ACUTE MYELOID LEUKEMIA

Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia, in Relapse;   NPM1 Mutation
Intervention:   Drug: Venetoclax+azacitidine
Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto
Not yet recruiting

Fri, 30 Apr 2021 12:00:00 EDT

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: Azacitidine combined to Lenalidomide
Sponsors:   Groupe Francophone des Myelodysplasies;   Celgene
Completed

Wed, 17 Mar 2010 12:00:00 EDT

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

Conditions:   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Myeloproliferative Neoplasm;   Chronic Myelomonocytic Leukemia
Interventions:   Drug: APR-246;   Drug: Azacitidine
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Aprea Therapeutics
Active, not recruiting

Tue, 07 Mar 2017 12:00:00 EST

Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

Conditions:   Myelodysplastic Syndromes;   Acute Myelogenous Leukemia
Interventions:   Drug: Azacitidine;   Drug: Lenalidomide
Sponsors:   Technische Universität Dresden;   Celgene Corporation
Terminated

Thu, 18 Jun 2009 12:00:00 EDT

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Interventions:   Drug: Azacitidine;   Drug: CC-486
Sponsors:   Kirby Institute;   Celgene
Active, not recruiting

Tue, 10 Apr 2018 12:00:00 EDT

Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia

Condition:   Acute Myeloid Leukaemia
Intervention:   Drug: S 64315 (also referred as MIK665) and azacitidine
Sponsors:   Institut de Recherches Internationales Servier;   ADIR, a Servier Group company
Recruiting

Mon, 16 Nov 2020 12:00:00 EST

Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

Condition:   Acute Myeloid Leukemia in Remission
Interventions:   Drug: Azacitidine;   Drug: Lenalidomide
Sponsor:   Ge Zheng
Recruiting

Wed, 29 Jul 2020 12:00:00 EDT

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

Conditions:   MDS;   AML;   Solid Tumors;   Multiple Myeloma;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease
Intervention:   Drug: azacitidine
Sponsor:   Celgene
Completed

Fri, 04 Apr 2008 12:00:00 EDT

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Conditions:   Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Myeloid, Acute
Interventions:   Drug: Azacitidine;   Drug: Pevonedistat
Sponsor:   Millennium Pharmaceuticals, Inc.
Active, not recruiting

Thu, 31 Aug 2017 12:00:00 EDT

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Conditions:   Acute Bilineal Leukemia;   Acute Biphenotypic Leukemia;   Chronic Myelomonocytic Leukemia;   IDH2 Gene Mutation;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Enasidenib Mesylate
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Unknown status

Tue, 25 Sep 2018 12:00:00 EDT

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm
Interventions:   Drug: Azacitidine;   Drug: BRD4 Inhibitor PLX51107
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Wed, 17 Jul 2019 12:00:00 EDT

A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

Condition:   Chronic Myelomonocytic Leukemia
Intervention:   Drug: 5-Azacitidine
Sponsors:   University of Utah;   Celgene
Completed

Tue, 10 May 2011 12:00:00 EDT

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement

Conditions:   Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL;   Leukemia Cutis;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Pinometostat
Sponsor:   National Cancer Institute (NCI)
Completed

Wed, 10 Oct 2018 12:00:00 EDT

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Conditions:   Leukemia;   Acute Myeloid Leukemia;   Relapsed/Refractory Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Intervention:   Drug: MAX-40279-01
Sponsor:   Maxinovel Pty., Ltd.
Recruiting

Wed, 29 Sep 2021 12:00:00 EDT

Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: Azacitidine and oral vorinostat
Sponsors:   Groupe Francophone des Myelodysplasies;   Merck Sharp & Dohme Corp.
Terminated

Wed, 12 Dec 2012 12:00:00 EST

A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: Oral azacitidine
Sponsor:   Celgene
Completed

Thu, 05 Apr 2012 12:00:00 EDT

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Conditions:   Newly Diagnosed Acute Myeloid Leukemia (AML);   Untreated AML;   AML Arising From Myelodysplastic Syndrome (MDS);   Leukemia, Myeloid, Acute
Interventions:   Drug: AG-120 (ivosidenib) with Azacitidine;   Drug: Placebo with Azacitidine
Sponsor:   Institut de Recherches Internationales Servier
Active, not recruiting

Thu, 01 Jun 2017 12:00:00 EDT

Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Conditions:   Diffuse Large B Cell Lymphoma;   Relapsed Non Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
Intervention:   Drug: azacitidine plus R-GDP
Sponsor:   Seoul National University Hospital
Not yet recruiting

Thu, 25 Oct 2018 12:00:00 EDT

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Conditions:   Myelodysplastic Syndrome;   Myelodysplastic Syndromes
Interventions:   Drug: GSK2879552;   Drug: Azacitidine
Sponsors:   GlaxoSmithKline;   Parexel
Terminated

Tue, 11 Oct 2016 12:00:00 EDT

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Conventional Care Regimen
Sponsor:   Celgene
Completed

Wed, 24 Feb 2010 12:00:00 EST

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Conditions:   Acute Bilineal Leukemia;   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia;   Mixed Phenotype Acute Leukemia;   T Acute Lymphoblastic Leukemia;   Therapy-Related Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Venetoclax
Sponsor:   M.D. Anderson Cancer Center
Recruiting

Wed, 16 Oct 2019 12:00:00 EDT

5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)

Conditions:   Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia
Interventions:   Procedure: allogeneic stem cell transplantation;   Procedure: 5-azacytidine until progress
Sponsor:   Universitätsklinikum Hamburg-Eppendorf
Unknown status

Thu, 28 Jul 2011 12:00:00 EDT

Azacitidine and Venetoclax in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

Conditions:   Acute Myeloid Leukemia in Remission;   FLT3 Gene Mutation;   Hematologic and Lymphocytic Disorder;   High Risk Acute Myeloid Leukemia;   Minimal Residual Disease Persistence;   Therapy-Related Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Genentech, Inc.
Recruiting

Tue, 20 Aug 2019 12:00:00 EDT

Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

Conditions:   Aml;   AML, Adult
Interventions:   Drug: Nivolumab;   Drug: Azacitidine
Sponsor:   Sherif Farag
Withdrawn

Wed, 16 Oct 2019 12:00:00 EDT

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia;   Blasts 20-30 Percent of Bone Marrow Nucleated Cells;   Blasts 20-30 Percent of Peripheral Blood White Cells;   Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   IPSS Risk Category Intermediate-2;   Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Glutaminase Inhibitor CB-839
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Thu, 09 Feb 2017 12:00:00 EST

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Myeloid, Acute
Interventions:   Drug: Azacitidine;   Drug: Pevonedistat
Sponsor:   Millennium Pharmaceuticals, Inc.
Completed

Fri, 20 Nov 2015 12:00:00 EST

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

Conditions:   Acute Myeloid Leukemia;   AML, Adult
Interventions:   Drug: evorpacept;   Drug: venetoclax;   Drug: azacitidine
Sponsor:   ALX Oncology Inc.
Recruiting

Tue, 16 Feb 2021 12:00:00 EST

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Conditions:   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Chronic Myelomonocytic Leukemia;   Refractory Myelodysplastic Syndrome;   Therapy-Related Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Genentech, Inc.
Recruiting

Wed, 16 Sep 2020 12:00:00 EDT

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: Azacitidine
Sponsor:   Celgene
Completed

Wed, 15 Sep 2010 12:00:00 EDT

Azacytidine Plus FLAG for Relapsed or Refractory AML

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Azacytidine;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Filgrastim
Sponsor:   King Fahad Medical City
Unknown status

Mon, 27 Oct 2014 12:00:00 EDT

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Conditions:   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Myelodysplastic Syndrome;   Refractory Myelodysplastic Syndrome;   Therapy-Related Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Tue, 12 Nov 2019 12:00:00 EST

Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities

Conditions:   Myelodysplastic Syndromes;   Leukemia, Myeloid, Acute
Intervention:   Drug: 5 azacytidine
Sponsor:   King's College London
Completed

Mon, 08 Jun 2009 12:00:00 EDT

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Condition:   Leukemia
Interventions:   Drug: Azacytidine;   Drug: Sorafenib
Sponsors:   M.D. Anderson Cancer Center;   Bayer
Completed

Tue, 22 Jul 2014 12:00:00 EDT

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Condition:   Leukemia
Interventions:   Drug: Brentuximab Vedotin;   Drug: 5-Azacytidine
Sponsors:   M.D. Anderson Cancer Center;   Seagen Inc.
Terminated

Wed, 26 Mar 2014 12:00:00 EDT

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: SyB C-1101 and Azacytidine
Sponsor:   SymBio Pharmaceuticals
Unknown status

Thu, 26 May 2016 12:00:00 EDT

MRD-guided Treatment in NPM1mut AML Patients

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Pembrolizumab;   Drug: Azacitidine
Sponsors:   Technische Universität Dresden;   Merck Sharp & Dohme Corp.
Recruiting

Fri, 07 Dec 2018 12:00:00 EST

Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Lenalidomide;   Other: Off Therapy
Sponsors:   University of Colorado, Denver;   Celgene
Completed

Thu, 06 Dec 2012 12:00:00 EST

Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)

Conditions:   Acute Myeloid Leukemia (AML);   Adult Acute Myeloblastic Leukemia
Interventions:   Drug: Lenalidomide;   Drug: Azacitidine
Sponsors:   Stanford University;   Celgene Corporation
Completed

Thu, 30 Apr 2009 12:00:00 EDT

Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

Conditions:   High Risk Myelodysplastic Syndrome;   IPSS Risk Category Intermediate-1;   Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Biological: Pembrolizumab
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting

Wed, 29 Mar 2017 12:00:00 EDT

Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma

Condition:   Multiple Myeloma
Intervention:   Drug: Azacitidine
Sponsors:   Virginia Commonwealth University;   National Cancer Institute (NCI);   Celgene Corporation
Completed

Fri, 15 Jan 2010 12:00:00 EST

Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes;   Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention:   Drug: Azacitidine
Sponsors:   Washington University School of Medicine;   The Foundation for Barnes-Jewish Hospital;   National Cancer Institute (NCI);   National Institutes of Health (NIH)
Terminated

Tue, 11 Dec 2012 12:00:00 EST

Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Condition:   Squamous Cell Carcinoma
Interventions:   Drug: Azacitidine;   Drug: Cisplatin
Sponsors:   University of Kansas Medical Center;   Celgene Corporation
Terminated

Mon, 05 Mar 2007 12:00:00 EST

Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults With Recurrent or Residual Posterior Fossa Ependymoma

Condition:   Fossa Ependymoma
Intervention:   Drug: 5-Azacytidine and trastuzumab infusion
Sponsor:   The University of Texas Health Science Center, Houston
Recruiting

Mon, 12 Jul 2021 12:00:00 EDT

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic
Interventions:   Drug: MBG453;   Drug: Azacitidine;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Recruiting

Wed, 12 Feb 2020 12:00:00 EST

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: Oral Azacitidine;   Drug: Placebo
Sponsor:   Celgene
Active, not recruiting

Mon, 31 Dec 2012 12:00:00 EST

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: azacitidine;   Drug: standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine
Sponsors:   University Hospital Muenster;   Celgene Corporation;   Amgen
Completed

Fri, 05 Jun 2009 12:00:00 EDT

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Condition:   Myelodysplastic Syndromes (MDS)
Interventions:   Drug: venetoclax;   Drug: azacitidine
Sponsors:   AbbVie;   Celgene; Genentech, Inc.
Active, not recruiting

Thu, 17 Nov 2016 12:00:00 EST

Azacitidine and Pembrolizumab in Pancreatic Cancer

Condition:   Pancreas Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Azacitidine
Sponsor:   Rachael A Safyan, MD
Recruiting

Tue, 29 Aug 2017 12:00:00 EDT

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

Condition:   High Risk MDS
Interventions:   Drug: Azacitidine;   Drug: Azacitidine plus Deferasirox
Sponsor:   Novartis Pharmaceuticals
Terminated

Mon, 09 Jun 2014 12:00:00 EDT

A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Azacitidine
Sponsors:   Anuradha Krishnamurthy;   Merck Sharp & Dohme Corp.
Completed

Thu, 09 Oct 2014 12:00:00 EDT

Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: DA
Sponsors:   Karolinska University Hospital;   Celgene Corporation
Terminated

Mon, 18 Feb 2013 12:00:00 EST

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

Condition:   Leukemia
Interventions:   Drug: Azacitidine;   Drug: Sorafenib
Sponsors:   M.D. Anderson Cancer Center;   Bayer;   Onyx Therapeutics, Inc.;   Celgene
Completed

Tue, 07 Dec 2010 12:00:00 EST

A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Azacitidine
Sponsors:   University of Kansas Medical Center;   Celgene
Terminated

Wed, 08 Jul 2009 12:00:00 EDT

COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

Conditions:   Recurrent Childhood CNS Tumor;   Ependymoma, Recurrent Childhood;   Childhood Solid Tumor
Intervention:   Drug: 5 Azacytidine
Sponsor:   The Hospital for Sick Children
Active, not recruiting

Sun, 02 Jul 2017 12:00:00 EDT

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Condition:   Advanced Solid Tumor Malignancies
Interventions:   Drug: 5-azacytidine, erlotinib;   Drug: Erlotinib PO and Vidaza IV
Sponsor:   New Mexico Cancer Care Alliance
Completed

Fri, 16 Oct 2009 12:00:00 EDT

SY-1425 Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: SY-1425;   Drug: Venetoclax;   Drug: Azacitidine
Sponsor:   Syros Pharmaceuticals
Recruiting

Thu, 27 May 2021 12:00:00 EDT

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma

Condition:   Recurrent Ependymoma
Interventions:   Drug: 5-Azacytidine (5-AZA) group 1;   Drug: 5-Azacytidine (5-AZA) group 2;   Drug: 5-Azacytidine (5-AZA) group 3
Sponsor:   The University of Texas Health Science Center, Houston
Recruiting

Thu, 28 Jun 2018 12:00:00 EDT

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   AML;   MDS
Interventions:   Drug: CX-01;   Drug: Azacitidine;   Procedure: Bone marrow biopsy;   Procedure: Peripheral blood draw
Sponsors:   Washington University School of Medicine;   Cantex Pharmaceuticals
Completed

Fri, 16 Dec 2016 12:00:00 EST

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions:   Drug: Azacitidine;   Drug: SL-401;   Drug: Venetoclax
Sponsors:   Dana-Farber Cancer Institute;   Stemline Therapeutics, Inc.
Recruiting

Thu, 13 Apr 2017 12:00:00 EDT

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Conditions:   Myelodysplastic Syndromes (MDS);   Acute Myelogenous Leukemia (AML)
Intervention:   Drug: low dose 5'-azacitidine
Sponsor:   Memorial Sloan Kettering Cancer Center
Active, not recruiting

Tue, 26 Nov 2013 12:00:00 EST

PKC412 and 5-Azacytidine

Condition:   Leukemia
Interventions:   Drug: 5-azacytidine;   Drug: PKC412
Sponsors:   M.D. Anderson Cancer Center;   Novartis Pharmaceuticals;   Celgene Corporation
Completed

Thu, 16 Sep 2010 12:00:00 EDT

Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions:   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Pevonedistat
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Mon, 19 Nov 2018 12:00:00 EST

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: lintuzumab;   Drug: 5-azacytidine
Sponsors:   Alison Walker;   Seagen Inc.
Terminated

Mon, 19 Oct 2009 12:00:00 EDT

A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Atezolizumab;   Drug: Azacitidine
Sponsor:   Hoffmann-La Roche
Completed

Mon, 27 Jul 2015 12:00:00 EDT

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Condition:   Leukemia
Interventions:   Drug: 5-azacitidine;   Procedure: Allogeneic Hematopoietic Cell Transplantation (HCT)
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Celgene Corporation
Completed

Thu, 17 Apr 2008 12:00:00 EDT

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Conditions:   Melanoma and Other Malignant Neoplasms of Skin;   Metastatic Melanoma
Interventions:   Drug: Azacitidine;   Drug: Pembrolizumab
Sponsors:   M.D. Anderson Cancer Center;   Merck Sharp & Dohme Corp.;   Celgene
Recruiting

Tue, 28 Jun 2016 12:00:00 EDT

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Pracinostat;   Drug: Azacitidine
Sponsor:   Helsinn Healthcare SA
Completed

Fri, 12 May 2017 12:00:00 EDT

Vidaza to Restore Hormone Thx Prostate

Condition:   Prostate Cancer
Intervention:   Drug: azacitidine for injectable suspension
Sponsors:   US Oncology Research;   Celgene Corporation;   University of Southern California
Completed

Fri, 06 Oct 2006 12:00:00 EDT

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

Condition:   Myelodysplastic Syndrome (MDS)
Interventions:   Drug: sabatolimab;   Drug: azacitidine;   Drug: venetoclax
Sponsor:   Novartis Pharmaceuticals
Recruiting

Tue, 23 Mar 2021 12:00:00 EDT

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

Conditions:   Acute Myelogenous Leukemia AML;   Myelodysplastic Syndrome MDS
Intervention:   Drug: Vidaza and Valproic Acid
Sponsor:   Patrick Stiff
Recruiting

Mon, 28 Apr 2014 12:00:00 EDT

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Conditions:   Acute Myeloid Leukemia (AML);   Minimal Residual Disease
Interventions:   Drug: Azacitidine;   Drug: Avelumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   Pfizer
Withdrawn

Tue, 09 Oct 2018 12:00:00 EDT

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Biological: Sargramostim
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI)
Completed

Thu, 04 Oct 2012 12:00:00 EDT

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Conditions:   Acute Myeloid Leukemia (AML);   Cancer
Interventions:   Drug: venetoclax;   Drug: azacytidine;   Drug: decitabine
Sponsor:   AbbVie
Active, not recruiting

Wed, 08 May 2019 12:00:00 EDT

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

Conditions:   Hematologic Malignancy;   Stem Cell Transplant Complications
Intervention:   Drug: Azacitidine in Combination With Venetoclax
Sponsors:   First Affiliated Hospital of Zhejiang University;   Second Affiliated Hospital, School of Medicine, Zhejiang University;   Zhejiang Provincial People's Hospital;   The First Affiliated Hospital of Zhejiang Chinese Medical University;   Sir Run Run Shaw Hospital;   First Affiliated Hospital of Wenzhou Medical University;   Ningbo No. 1 Hospital;   Yinzhou Hospital Affiliated to Medical School of Ningbo University;   Jinhua Central Hospital;   Taizhou Hospital;   Union hospital of Fujian Medical University;   Xiangya Hospital of Central South University
Recruiting

Mon, 22 Mar 2021 12:00:00 EDT

Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
Intervention:   Drug: 5-azacitidine
Sponsor:   Grupo Cooperativo de Hemopatías Malignas
Withdrawn

Thu, 05 Mar 2020 12:00:00 EST

Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: Azacitidine
Sponsors:   Loyola University;   Celgene Corporation
Withdrawn

Thu, 12 Feb 2009 12:00:00 EST

5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Condition:   Leukemia
Interventions:   Drug: 5-Azacytidine;   Drug: Lenalidomide
Sponsors:   M.D. Anderson Cancer Center;   Celgene
Completed

Thu, 24 Dec 2009 12:00:00 EST

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: azacitidine;   Drug: lenalidomide
Sponsors:   Mikkael Sekeres MD;   National Cancer Institute (NCI)
Completed

Fri, 14 Jul 2006 12:00:00 EDT

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Acute Myelogenous Leukemia
Interventions:   Drug: Azacitidine;   Drug: Lenalidomide;   Other: Best Supportive Care (BSC)
Sponsor:   Celgene
Completed

Tue, 24 May 2011 12:00:00 EDT

Study of Azacitidine and Durvalumab in Advanced Solid Tumors

Conditions:   Microsatellite Stable Colorectal Carcinoma;   Platinum Resistant Epithelial Ovarian Cancer Type II;   Estrogen Receptor Positive and HER2 Negative Breast Cancer
Interventions:   Drug: Azacitidine;   Drug: Durvalumab
Sponsor:   University Health Network, Toronto
Completed

Thu, 23 Jun 2016 12:00:00 EDT

Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: Birinapant;   Drug: 5-Azacitidine
Sponsor:   TetraLogic Pharmaceuticals
Completed

Wed, 10 Apr 2013 12:00:00 EDT

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Azacitidine;   Drug: Epoetin beta
Sponsors:   Groupe Francophone des Myelodysplasies;   Celgene Corporation;   Roche Pharma AG
Completed

Wed, 18 Nov 2009 12:00:00 EST

A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: Azacitidine;   Other: Control Arm
Sponsor:   Celgene
Completed

Thu, 21 May 2015 12:00:00 EDT

Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Condition:   Leukemia
Interventions:   Drug: Vorinostat;   Drug: Azacitidine
Sponsors:   M.D. Anderson Cancer Center;   Merck Sharp & Dohme Corp.;   Celgene Corporation
Completed

Wed, 29 Jul 2009 12:00:00 EDT

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Interventions:   Drug: Azacitidine;   Biological: Durvalumab
Sponsor:   Celgene
Active, not recruiting

Wed, 18 May 2016 12:00:00 EDT

Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

Condition:   Leukemia
Interventions:   Drug: Decitabine;   Drug: Azacitidine
Sponsor:   M.D. Anderson Cancer Center
Completed

Fri, 02 Nov 2012 12:00:00 EDT

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Conditions:   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Acute Myeloid Leukemia;   Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
Intervention:   Drug: Oral azacitidine
Sponsor:   Celgene Corporation
Terminated

Thu, 25 Jul 2013 12:00:00 EDT

A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS

Condition:   MDS
Intervention:   Drug: Deferasirox, Vitamin D and Azacitidine
Sponsors:   Groupe Francophone des Myelodysplasies;   Novartis
Unknown status

Wed, 31 Oct 2012 12:00:00 EDT

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Conditions:   Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Acute Myelogenous Leukemia (AML)
Interventions:   Drug: Subcutaneous (SC) Azacitidine;   Drug: Oral Azacitidine
Sponsor:   Celgene
Completed

Fri, 14 Sep 2007 12:00:00 EDT

AVIDA The Vidaza® (Azacitidine) Patient Registry

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: Azacitidine
Sponsor:   Celgene
Completed

Fri, 01 Jun 2007 12:00:00 EDT

A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML

Conditions:   Myelodysplastic Syndromes;   Chronic Myelocytic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome/Neoplasm
Interventions:   Drug: Azacitidine;   Drug: ASTX030 (cedazuridine + azacitidine);   Drug: Cedazuridine
Sponsor:   Astex Pharmaceuticals, Inc.
Recruiting

Wed, 05 Feb 2020 12:00:00 EST

Azacitidine and Homoharringtonine in JMML

Condition:   JMML
Intervention:   Drug: Azacitidine and homoharringtonine
Sponsors:   Air Force Military Medical University, China;   Qilu Hospital of Shandong University;   Taian City Central Hospital;   The Affiliated Hospital of Qingdao University;   The Second Hospital of Hebei Medical University;   Children's Hospital of Hebei Province
Recruiting

Mon, 10 Aug 2020 12:00:00 EDT

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Uproleselan;   Drug: Venetoclax
Sponsors:   Brian Jonas;   GlycoMimetics Incorporated;   National Cancer Institute (NCI)
Recruiting

Fri, 16 Jul 2021 12:00:00 EDT

Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML

Condition:   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Pevonedistat;   Procedure: transplant;   Drug: Azacitidine
Sponsors:   Milton S. Hershey Medical Center;   Millennium Pharmaceuticals, Inc.;   Takeda
Terminated

Wed, 17 Oct 2018 12:00:00 EDT

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Conditions:   MDS;   Myelodysplastic Syndromes
Intervention:   Drug: APR-548 + Azacitidine
Sponsor:   Aprea Therapeutics
Recruiting

Fri, 20 Nov 2020 12:00:00 EST

Pharmacokinetics, Tolerability and Safety of NEX-18a

Conditions:   Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Acute Myeloid Leukemia (AML)
Interventions:   Drug: NEX-18a injection;   Drug: Azacitidine Injection
Sponsors:   Nanexa AB;   Uppsala University
Recruiting

Fri, 17 Sep 2021 12:00:00 EDT

A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome (MDS)
Interventions:   Drug: FF-10501-01;   Drug: Azacitidine
Sponsor:   Fujifilm Pharmaceuticals U.S.A., Inc.
Withdrawn

Tue, 03 Apr 2018 12:00:00 EDT

Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions:   Drug: Azacitidine;   Other: Diagnostic Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 21 Jan 2011 12:00:00 EST

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Conditions:   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)
Intervention:   Drug: MGCD0103 and Azacitidine
Sponsor:   Mirati Therapeutics Inc.
Terminated

Mon, 15 Oct 2007 12:00:00 EDT

Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma

Conditions:   Lymphoma;   Hodgkin Disease;   Lymphoma, Non-Hodgkin
Intervention:   Drug: Azacitidine with rituximab, vincristine, and cyclophosphamide
Sponsors:   Shams Shakil;   Celgene
Completed

Wed, 13 May 2009 12:00:00 EDT

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A;   Fibroblast Growth Factor Basic Form Measurement;   FLT3 Internal Tandem Duplication;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis;   Drug: Nintedanib
Sponsors:   Northwestern University;   Robert H. Lurie Cancer Center;   Boehringer Ingelheim;   National Cancer Institute (NCI)
Recruiting

Tue, 01 May 2018 12:00:00 EDT

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Conditions:   Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia
Interventions:   Drug: Azacitidine;   Drug: Erythropoetin
Sponsor:   Nordic MDS Group
Completed

Wed, 13 Jan 2010 12:00:00 EST

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

Conditions:   Myeloid Leukemia;   Myelodysplastic Syndromes
Interventions:   Other: blood samples;   Drug: azacytidine
Sponsor:   Assistance Publique Hopitaux De Marseille
Unknown status

Fri, 03 Jul 2015 12:00:00 EDT

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Conditions:   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Myelodysplastic/Myeloproliferative Neoplasm;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelomonocytic Leukemia;   Refractory Myelodysplastic/Myeloproliferative Neoplasm
Interventions:   Drug: Azacitidine;   Drug: Gilteritinib;   Drug: Venetoclax
Sponsor:   M.D. Anderson Cancer Center
Recruiting

Mon, 28 Oct 2019 12:00:00 EDT

Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions:   Drug: azacitidine;   Other: laboratory biomarker analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   Celgene Corporation;   National Cancer Institute (NCI)
Completed

Wed, 10 Mar 2010 12:00:00 EST

Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic
Interventions:   Drug: Azacitidine;   Drug: Volasertib
Sponsor:   Boehringer Ingelheim
Completed

Mon, 28 Jul 2014 12:00:00 EDT

Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence

Conditions:   HSCT;   Efficacy and Safety
Intervention:   Drug: Azacitidine combined with interferon preemptive treatment
Sponsor:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Recruiting

Fri, 06 Sep 2019 12:00:00 EDT

A Phase II Study of Maintenance With Azacitidine in MDS Patients

Conditions:   Leukemia, Myelocytic, Acute;   Myelodysplastic Syndromes
Intervention:   Drug: Azacitidine
Sponsors:   Groupe Francophone des Myelodysplasies;   Celgene Corporation
Terminated

Mon, 12 Mar 2007 12:00:00 EDT

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Azacitidine;   Drug: Erythropoietin;   Drug: Azacitidine (Monotherapy)
Sponsors:   Larry Cripe, MD;   Celgene Corporation;   Ortho Biotech Clinical Affairs, L.L.C.;   Walther Cancer Institute
Terminated

Mon, 25 Sep 2006 12:00:00 EDT

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Condition:   AML, Childhood
Interventions:   Drug: Nivolumab;   Drug: 5-azacytidine
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Bristol-Myers Squibb
Recruiting

Thu, 31 Jan 2019 12:00:00 EST

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

Conditions:   Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML)
Interventions:   Drug: birinapant;   Drug: Azacitidine;   Drug: Placebo
Sponsor:   TetraLogic Pharmaceuticals
Terminated

Wed, 28 May 2014 12:00:00 EDT

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Condition:   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Azacitidine;   Drug: Venetoclax;   Drug: Placebo
Sponsors:   AbbVie;   Genentech, Inc.
Active, not recruiting

Thu, 15 Dec 2016 12:00:00 EST

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Conditions:   Relapsed Angioimmunoblastic T-Cell Lymphoma;   Refractory Angioimmunoblastic T-cell Lymphoma
Interventions:   Drug: Oral azacitidine;   Drug: Romidepsin;   Drug: Bendamustine;   Drug: Gemcitabine
Sponsors:   The Lymphoma Academic Research Organisation;   Celgene
Active, not recruiting

Thu, 19 Jul 2018 12:00:00 EDT

Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

Condition:   Acute Myelogenous Leukemia
Interventions:   Drug: MLN4924;   Drug: Azacitidine
Sponsor:   Millennium Pharmaceuticals, Inc.
Completed

Wed, 20 Mar 2013 12:00:00 EDT

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Myelodysplastic Syndrome With Isolated Del(5q);   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia
Interventions:   Drug: Sirolimus;   Drug: Azacitidine
Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
Active, not recruiting

Wed, 05 Jun 2013 12:00:00 EDT

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Conditions:   Prostatic Neoplasms;   Prostate Neoplasms;   Prostate Cancer
Interventions:   Drug: 5-Azacitidine;   Drug: all trans retinoic acid;   Drug: Lupron
Sponsor:   Icahn School of Medicine at Mount Sinai
Recruiting

Thu, 28 Jun 2018 12:00:00 EDT

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine for Injection;   Drug: Vidaza®
Sponsor:   Bioniche Pharma USA LLC
Completed

Tue, 29 Jun 2010 12:00:00 EDT

Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: azacitidine
Sponsor:   Celgene
Completed

Tue, 01 Feb 2005 12:00:00 EST

Azacitidine in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions:   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsors:   Albert Einstein College of Medicine;   National Cancer Institute (NCI)
Completed

Thu, 12 Dec 2013 12:00:00 EST

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: MBG453;   Drug: Venetoclax;   Drug: Azacitidine
Sponsor:   Novartis Pharmaceuticals
Recruiting

Mon, 04 Nov 2019 12:00:00 EST

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML

Conditions:   Immunotherapy;   Refractory Leukemia;   Relapsed Adult AML;   Acute Myeloid Leukemia
Intervention:   Drug: Visilizumab
Sponsor:   The First Affiliated Hospital of Soochow University
Recruiting

Mon, 25 Jan 2021 12:00:00 EST

Action of the Vidaza on the Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Acute Leukemia
Intervention:   Other: Effect of Vidaza treatment
Sponsor:   Hospices Civils de Lyon
Recruiting

Mon, 02 Oct 2017 12:00:00 EDT

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: vadastuximab talirine;   Drug: Azacitidine;   Drug: Placebo (for 33A)
Sponsor:   Seagen Inc.
Terminated

Fri, 11 Mar 2016 12:00:00 EST

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Conditions:   Acute Myeloid Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: FT-2102 (olutasidenib);   Drug: Azacitidine;   Drug: Cytarabine
Sponsor:   Forma Therapeutics, Inc.
Recruiting

Fri, 25 Mar 2016 12:00:00 EDT

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: pracinostat;   Drug: Placebo;   Drug: Azacitidine
Sponsor:   Helsinn Healthcare SA
Completed

Mon, 10 Jun 2013 12:00:00 EDT

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Conditions:   Acute Myeloid Leukemia in Remission;   Myelodysplastic Syndromes;   Minimal Residual Disease
Interventions:   Drug: Pevonedistat;   Drug: Azacitidine
Sponsors:   University of Leipzig;   Millennium Pharmaceuticals, Inc.
Recruiting

Tue, 19 Jan 2021 12:00:00 EST

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Conditions:   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelomonocytic Leukemia;   Refractory Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Trametinib;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Mon, 27 Jul 2020 12:00:00 EDT

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: decitabine;   Drug: azacitidine
Sponsor:   Eisai Inc.
Terminated

Wed, 11 Nov 2009 12:00:00 EST

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Myeloid, Acute
Intervention:   Drug: oral azacitidine
Sponsor:   Celgene
Completed

Thu, 26 Jan 2012 12:00:00 EST

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Omacetaxine;   Drug: Azacitidine;   Drug: G-CSF
Sponsors:   University of Florida;   Teva Pharmaceutical Industries, Ltd.
Withdrawn

Mon, 18 Jul 2016 12:00:00 EDT

Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia

Conditions:   Myelodysplastic Syndrome;   Myelofibrosis;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia
Interventions:   Drug: Luitpold Azacitidine;   Drug: Vidaza®
Sponsor:   American Regent, Inc.
Completed

Mon, 07 Feb 2011 12:00:00 EST

Azacytidine and Valproic Acid in Patients With Advanced Cancers

Condition:   Advanced Cancers
Interventions:   Drug: Azacitidine;   Drug: Valproic Acid
Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
Completed

Wed, 04 Jul 2007 12:00:00 EDT

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Condition:   Myelodysplastic Syndromes (MDS)
Interventions:   Drug: Azacitidine;   Drug: Venetoclax
Sponsors:   AbbVie;   Genentech, Inc.
Active, not recruiting

Mon, 24 Oct 2016 12:00:00 EDT

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

Condition:   Peripheral T-cell Lymphoma
Interventions:   Drug: Azacitidine;   Drug: Chidamide
Sponsor:   Ruijin Hospital
Recruiting

Tue, 21 Jul 2020 12:00:00 EDT

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Biological: Magrolimab;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Wed, 17 Jun 2020 12:00:00 EDT

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

Condition:   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Pevonedistat;   Drug: Venetoclax;   Drug: Azacitidine
Sponsor:   Takeda
Active, not recruiting

Wed, 12 Feb 2020 12:00:00 EST

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions:   Drug: Vidaza;   Drug: Velcade
Sponsors:   Ohio State University Comprehensive Cancer Center;   Millennium Pharmaceuticals, Inc.;   Celgene Corporation
Completed

Thu, 28 Feb 2008 12:00:00 EST

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Magrolimab;   Drug: Azacitidine;   Drug: Placebo
Sponsor:   Gilead Sciences
Recruiting

Wed, 18 Mar 2020 12:00:00 EDT

Azacytidine During Anti-tuberculosis Therapy

Condition:   Tuberculosis, Pulmonary
Intervention:   Drug: Azacitidine Injection
Sponsors:   Andrew Dinardo;   Bristol-Myers Squibb
Not yet recruiting

Wed, 08 May 2019 12:00:00 EDT

Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL

Condition:   Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Interventions:   Drug: Revlimid;   Drug: Azacitidine
Sponsors:   Hackensack Meridian Health;   Celgene Corporation
Terminated

Tue, 16 Nov 2010 12:00:00 EST

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Conditions:   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Acute Myeloid Leukemia
Interventions:   Drug: Panobinostat (LBH589);   Drug: 5-Azacytidine
Sponsor:   Novartis Pharmaceuticals
Completed

Mon, 27 Jul 2009 12:00:00 EDT

Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT

Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic
Interventions:   Drug: Lenalidomide;   Drug: Azacitidine;   Biological: Donor Lymphocyte Infusions
Sponsors:   Heinrich-Heine University, Duesseldorf;   Celgene Corporation
Completed

Tue, 16 Jun 2015 12:00:00 EDT

A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: AG-120;   Drug: Azacitidine;   Drug: AG-221
Sponsor:   Celgene
Active, not recruiting

Tue, 09 Feb 2016 12:00:00 EST

Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions:   Drug: Azacitidine 30mg/m2;   Drug: Entinostat;   Drug: Azacitidine 40mg/m2
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 13 Oct 2006 12:00:00 EDT

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Conditions:   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Biological: Lirilumab
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Terminated

Thu, 26 Mar 2015 12:00:00 EDT

VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Other: DLI
Sponsor:   Nantes University Hospital
Completed

Wed, 29 Feb 2012 12:00:00 EST

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

Condition:   Hematological Malignancies
Interventions:   Drug: Magrolimab;   Drug: Azacitidine
Sponsor:   Gilead Sciences
Recruiting

Mon, 14 Aug 2017 12:00:00 EDT

Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Avelumab;   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Terminated

Wed, 02 Nov 2016 12:00:00 EDT

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Conditions:   Acute Myeloid Leukemia (AML);   Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Interventions:   Drug: gilteritinib;   Drug: azacitidine
Sponsor:   Astellas Pharma Global Development, Inc.
Active, not recruiting

Tue, 26 Apr 2016 12:00:00 EDT

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

Conditions:   Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: Azacitidine Injection;   Drug: sodium phenylbutyrate
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI)
Completed

Mon, 27 Jan 2003 12:00:00 EST

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia
Interventions:   Drug: Glasdegib;   Drug: Azacitidine
Sponsor:   Pfizer
Active, not recruiting

Tue, 13 Apr 2021 12:00:00 EDT

Azacitidine and Lenalidomide for Acute Myeloid Leukemia

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: Lenalidomide;   Drug: Azacitidine
Sponsors:   Washington University School of Medicine;   Celgene Corporation
Completed

Thu, 19 Nov 2009 12:00:00 EST

5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS

Conditions:   Acute Myelogenous Leukaemia (AML);   Myelodysplastic Syndrome (MDS)
Intervention:   Drug: 5 azacytidine - VALPROIC acid- Retinoic acid
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed

Tue, 20 Jun 2006 12:00:00 EDT

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Interventions:   Drug: Azacitidine;   Drug: MGCD0103
Sponsor:   Mirati Therapeutics Inc.
Terminated

Fri, 25 Apr 2008 12:00:00 EDT

Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: 5-Azacytidine and Lenalidomide
Sponsor:   Tel-Aviv Sourasky Medical Center
Unknown status

Thu, 21 Jan 2010 12:00:00 EST

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Eosinophilic Leukemia, Not Otherwise Specified;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloid Neoplasm;   Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm, Unclassifiable;   Overt Primary Myelofibrosis;   Polycythemia Vera;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Prefibrotic/Early Primary Myelofibrosis
Interventions:   Drug: Azacitidine;   Drug: Pevonedistat;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Tue, 05 Mar 2019 12:00:00 EST

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Condition:   Leukemia
Interventions:   Drug: Azacitidine (AZA);   Drug: Tyrosine kinase inhibitor (TKI);   Drug: Azacitidine
Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
Completed

Thu, 27 Oct 2011 12:00:00 EDT

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Condition:   Leukemia
Interventions:   Drug: Azacitidine (AZA) Days 1 - 3;   Drug: Decitabine (DAC);   Other: Best Supportive Care (BSC);   Drug: Azacitidine (AZA) Days 1 - 5
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting

Tue, 21 Oct 2014 12:00:00 EDT

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Conditions:   Acute Myeloid Leukemia;   Hematopoietic and Lymphoid System Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Ivosidenib;   Drug: Venetoclax
Sponsor:   M.D. Anderson Cancer Center
Recruiting

Tue, 20 Mar 2018 12:00:00 EDT

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Conditions:   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer
Interventions:   Drug: CC-223, erlotinib;   Drug: CC-223, oral azacitidine
Sponsor:   Celgene
Completed

Wed, 07 Mar 2012 12:00:00 EST

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Condition:   Lymphoma, T-Cell
Interventions:   Drug: Azacitidine;   Drug: Romidepsin;   Drug: Gemcitabine
Sponsor:   Celgene
Active, not recruiting

Fri, 12 Oct 2018 12:00:00 EDT

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Oral Azacitidine;   Drug: Durvalumab
Sponsor:   Celgene
Active, not recruiting

Sun, 02 Nov 2014 12:00:00 EDT

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

Condition:   Solid Tumors
Interventions:   Drug: Azacitidine;   Drug: Valproic Acid;   Drug: Carboplatin
Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
Completed

Fri, 14 Sep 2007 12:00:00 EDT

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Conditions:   Myelodysplastic Syndromes;   Myeloproliferative Neoplasm
Interventions:   Drug: Azacitidine Subcutaneous Injection or Intravenous Infusion;   Drug: Pevonedistat Infusion;   Procedure: Bone Marrow Biopsy & Aspirate
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Suspended

Thu, 03 Aug 2017 12:00:00 EDT

A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: OTX015;   Drug: Vidaza (azacitidine)
Sponsor:   Oncoethix GmbH
Withdrawn

Mon, 01 Dec 2014 12:00:00 EST

Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

Condition:   NK/T Cell Lymphoma
Intervention:   Drug: Dexamethasone, azacytidine, Pegaspargase, Tislelizumab
Sponsors:   Peking University;   Beijing Cancer Hospital
Not yet recruiting

Mon, 24 May 2021 12:00:00 EDT

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Leukemia
Interventions:   Drug: Azacitidine;   Drug: Ara-C
Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
Completed

Thu, 06 Dec 2007 12:00:00 EST

Phase II 5-Azacytidine Plus VPA Plus ATRA

Conditions:   Myelodysplastic Syndrome;   Acute Myelogenous Leukemia
Interventions:   Drug: 5-Azacytidine (5-aza);   Drug: Valproic Acid;   Drug: All-Trans Retinoic Acid (ATRA)
Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
Completed

Tue, 16 May 2006 12:00:00 EDT

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

Conditions:   Sarcomas;   Melanomas;   Germ Cell Tumors;   Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas);   Pulmonary Metastases
Interventions:   Device: AeroEclipse II Breath Actuated Nebulizer;   Drug: Bintrafusp alfa;   Drug: Azacytidine
Sponsor:   National Cancer Institute (NCI)
Recruiting

Wed, 02 Dec 2020 12:00:00 EST

Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Deferasirox;   Drug: Cholecalciferol;   Drug: Azacitidine
Sponsor:   Elizabeth Henry
Terminated

Mon, 19 Jan 2015 12:00:00 EST

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Conditions:   Leukemia;   FLT3-Mutated Acute Myeloid Leukemia;   FLT3-Mutated High-Risk Myelodysplastic Syndrome
Interventions:   Drug: Ponatinib;   Drug: 5-azacytidine;   Behavioral: Phone Calls
Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
Withdrawn

Tue, 12 Jul 2016 12:00:00 EDT

Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes

Conditions:   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Secondary Myelodysplastic Syndromes
Interventions:   Drug: azacitidine;   Biological: etanercept
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Completed

Mon, 11 Jul 2005 12:00:00 EDT

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Condition:   Lymphoma, T-Cell
Interventions:   Drug: Durvalumab;   Drug: Pralatrexate;   Drug: Romidepsin;   Drug: 5-Azacitidine
Sponsors:   Columbia University;   University of Bologna;   Samsung Medical Center;   Celgene
Recruiting

Fri, 19 May 2017 12:00:00 EDT

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions:   Drug: Azacitidine;   Biological: Daratumumab;   Drug: Dexamethasone
Sponsors:   University of California, San Francisco;   Janssen Pharmaceuticals;   Multiple Myeloma Research Foundation
Recruiting

Fri, 29 May 2020 12:00:00 EDT

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Conditions:   Acute Myeloid Leukemia;   Relapsed Adult AML
Interventions:   Biological: Lintuzumab-Ac225;   Drug: Venetoclax;   Drug: Azacitidine
Sponsor:   Actinium Pharmaceuticals
Not yet recruiting

Tue, 30 Apr 2019 12:00:00 EDT

A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

Conditions:   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Interventions:   Drug: PF-04449913 (Glasdegib);   Drug: Azacitidine
Sponsor:   Pfizer
Active, not recruiting

Fri, 20 Feb 2015 12:00:00 EST

A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Azacitidine;   Other: Physician Choice
Sponsor:   Celgene
Completed

Wed, 05 Nov 2003 12:00:00 EST

Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia

Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: azacitidine;   Drug: cytarabine;   Drug: mitoxantrone hydrochloride;   Other: laboratory biomarker analysis
Sponsors:   University of Chicago;   National Cancer Institute (NCI)
Completed

Wed, 24 Apr 2013 12:00:00 EDT

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Condition:   Leukemia
Interventions:   Drug: Lirilumab;   Drug: Nivolumab;   Drug: Azacitidine
Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
Terminated

Fri, 06 Nov 2015 12:00:00 EST

Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant

Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Interventions:   Drug: Azacitidine;   Drug: Pre-DLI Salvage Chemotherapy;   Biological: Donor Leukocyte Infusion (DLI)
Sponsors:   Washington University School of Medicine;   National Cancer Institute (NCI)
Completed

Mon, 11 Jul 2011 12:00:00 EDT

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Conditions:   Lymphoid Malignancies;   Lymphoma;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma
Interventions:   Drug: Romidepsin;   Drug: Oral 5-Azacitidine
Sponsors:   Columbia University;   Celgene
Terminated

Thu, 28 Nov 2013 12:00:00 EST


Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Conditions:   Osteosarcoma;   Osteosarcoma in Children;   Osteosarcoma Recurrent;   Sarcoma
Interventions:   Drug: Nivolumab;   Drug: Azacitidine;   Procedure: Post Treatment Surgery
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
Recruiting

Tue, 14 Aug 2018 12:00:00 EDT

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

Condition:   Advanced Cancers
Interventions:   Drug: Azacitidine;   Drug: Lenalidomide;   Drug: Grifola Frondosa
Sponsors:   M.D. Anderson Cancer Center;   Yukiguni Maitake Company Ltd.
Terminated

Mon, 13 Sep 2010 12:00:00 EDT

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Conditions:   Solid Tumors;   Hematologic Malignancies;   Myelodysplastic Syndrome
Interventions:   Drug: SB939;   Drug: Azacitidine
Sponsor:   S*BIO
Completed

Tue, 26 Aug 2008 12:00:00 EDT

Azacitidine in Treating Patients With Myelofibrosis

Conditions:   Chronic Myeloproliferative Disorders;   Secondary Myelofibrosis
Intervention:   Drug: azacitidine
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Terminated

Thu, 28 Sep 2006 12:00:00 EDT

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Gemtuzumab Ozogamicin
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Tue, 15 Apr 2008 12:00:00 EDT

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: IMGN632;   Drug: Venetoclax
Sponsors:   ImmunoGen, Inc.;   Jazz Pharmaceuticals
Recruiting

Wed, 11 Sep 2019 12:00:00 EDT

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Condition:   Myelodysplastic Syndromes (MDS)
Intervention:   Combination Product: Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
Sponsor:   Sumitomo Dainippon Pharma Oncology, Inc
Active, not recruiting

Fri, 20 Jul 2018 12:00:00 EDT

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: 5-Azacitidine;   Drug: Gemtuzumab ozogamicin
Sponsors:   University of California, San Diego;   Celgene Corporation;   Pfizer
Completed

Fri, 03 Oct 2008 12:00:00 EDT

Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Pevonedistat;   Drug: Azacitidine
Sponsor:   Takeda
No longer available

Thu, 23 Jul 2020 12:00:00 EDT

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

Conditions:   Adult Solid Neoplasm;   Hematopoietic and Lymphoid Cell Neoplasm
Interventions:   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 24 Dec 2009 12:00:00 EST

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: Oral Azacitidine;   Drug: Placebo;   Other: Best Supportiv Care (BSC)
Sponsor:   Celgene
Active, not recruiting

Thu, 29 Mar 2012 12:00:00 EDT

Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS

Condition:   High Grade Myelodysplastic Syndromes
Interventions:   Drug: Omacetaxine;   Drug: Azacitidine
Sponsor:   University of Colorado, Denver
Recruiting

Thu, 21 Jun 2018 12:00:00 EDT

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Condition:   Multiple Myeloma
Intervention:   Drug: Azacitidine
Sponsor:   Bayside Health
Terminated

Tue, 19 Dec 2006 12:00:00 EST

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Entinostat;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Wed, 12 Apr 2006 12:00:00 EDT

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Conditions:   Male Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
Interventions:   Drug: Azacitidine;   Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Mon, 09 May 2011 12:00:00 EDT

Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML

Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic
Interventions:   Drug: Azacitidine;   Drug: Volasertib
Sponsor:   Boehringer Ingelheim
Terminated

Tue, 08 Oct 2013 12:00:00 EDT

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome (MDS)
Interventions:   Drug: Venetoclax;   Drug: Azacitidine;   Drug: Placebo
Sponsors:   AbbVie;   Genentech, Inc.
Recruiting

Tue, 26 May 2020 12:00:00 EDT

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Essential Thrombocythemia;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndrome;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: Sonidegib
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Completed

Fri, 02 May 2014 12:00:00 EDT

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

Conditions:   Leukemia, Erythroblastic, Acute;   Myelodysplastic Syndromes
Interventions:   Drug: 5-Azacytidine;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Alemtuzumab;   Radiation: Total Body Irradiation
Sponsor:   Weill Medical College of Cornell University
Completed

Tue, 14 Jul 2015 12:00:00 EDT

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Conditions:   Follicular Lymphoma;   Marginal Zone Lymphoma
Interventions:   Drug: azacitidine;   Drug: lenalidomide
Sponsors:   Duke University;   Celgene
Terminated

Wed, 12 May 2010 12:00:00 EDT

Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

Conditions:   Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma
Interventions:   Drug: Azacitidine;   Drug: Entinostat;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Terminated

Thu, 23 Sep 2010 12:00:00 EDT

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Conditions:   Acute Erythroid Leukemia;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Ring Sideroblasts;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia
Interventions:   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vorinostat
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Thu, 26 Oct 2006 12:00:00 EDT

PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

Conditions:   CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE;   CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS
Interventions:   Drug: Ponatinib;   Drug: Azacitidine
Sponsor:   Versailles Hospital
Recruiting

Fri, 29 Mar 2019 12:00:00 EDT

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Condition:   Safety and Efficacy
Interventions:   Drug: Sintilimab;   Drug: Chidamide;   Drug: Azacitidine;   Drug: L-DEP
Sponsor:   Sun Yat-sen University
Not yet recruiting

Tue, 17 Aug 2021 12:00:00 EDT

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Conditions:   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7;   Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Interventions:   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vorinostat
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Mon, 12 Jun 2006 12:00:00 EDT

5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia

Condition:   Beta Thalassemia
Intervention:   Drug: 5-Azacytidine
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Fri, 07 Jul 2000 12:00:00 EDT

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Conditions:   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myelofibrosis Transformation in Essential Thrombocythemia;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis
Interventions:   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis;   Drug: Ruxolitinib Phosphate
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Fri, 08 Feb 2013 12:00:00 EST

A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Entinostat days 3, 10;   Drug: 5AC;   Drug: Entinostat days 10,17
Sponsor:   Hetty Carraway
Suspended

Mon, 28 Feb 2011 12:00:00 EST

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Conditions:   Acute Bilineal Leukemia;   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Wed, 25 Mar 2015 12:00:00 EDT

Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer
Intervention:   Drug: Vidaza
Sponsors:   University of Oklahoma;   Celgene Corporation
Terminated

Thu, 22 Jul 2010 12:00:00 EDT

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Leukemia
Interventions:   Drug: 5-Azacytidine;   Drug: Ara-C;   Drug: Valproic Acid (VPA)
Sponsor:   M.D. Anderson Cancer Center
Completed

Fri, 29 Sep 2006 12:00:00 EDT

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Conditions:   Accelerated Phase of Disease;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndrome;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Disease;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome
Interventions:   Drug: Belinostat;   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 14 Jul 2006 12:00:00 EDT

A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: AK117;   Drug: Azacitidine
Sponsor:   Akeso
Recruiting

Wed, 28 Jul 2021 12:00:00 EDT

A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: AK117;   Drug: Azacitidine
Sponsor:   Akeso
Recruiting

Tue, 25 May 2021 12:00:00 EDT

Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients

Conditions:   MDS;   CMML
Intervention:   Drug: CC-486
Sponsor:   University of Florence
Recruiting

Fri, 19 Mar 2021 12:00:00 EDT

Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: azacitidine;   Drug: Lenalidomide
Sponsors:   French Innovative Leukemia Organisation;   Celgene Corporation
Completed

Wed, 23 Feb 2011 12:00:00 EST

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Condition:   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Venetoclax;   Drug: Azacitidine;   Drug: Placebo for Venetoclax;   Drug: CC-486
Sponsors:   AbbVie;   Roche-Genentech
Recruiting

Wed, 25 Sep 2019 12:00:00 EDT

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Condition:   Lymphoma
Interventions:   Drug: azacytidine;   Drug: vorinostat
Sponsors:   Weill Medical College of Cornell University;   Celgene;   Merck Sharp & Dohme Corp.
Completed

Tue, 11 May 2010 12:00:00 EDT

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitdine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Interventions:   Drug: Lemzoparlimab;   Drug: Azacitidine;   Drug: Venetoclax
Sponsor:   AbbVie
Suspended

Thu, 03 Jun 2021 12:00:00 EDT

Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery

Conditions:   Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions:   Drug: Azacitidine;   Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Therapeutic Conventional Surgery
Sponsor:   National Cancer Institute (NCI)
Terminated

Wed, 26 Jun 2013 12:00:00 EDT

Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome)

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: 5-aza-cytidine and Thalidomide
Sponsor:   Tel-Aviv Sourasky Medical Center
Unknown status

Wed, 25 Jun 2008 12:00:00 EDT

Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Volasertib;   Drug: Azacitidine
Sponsor:   Boehringer Ingelheim
Terminated

Tue, 29 Mar 2016 12:00:00 EDT

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

Conditions:   Acute Myeloid Leukemia (AML);   Cancer
Interventions:   Drug: Venetoclax;   Drug: Azacitidine;   Other: Best Supportive Care (BSC)
Sponsor:   AbbVie
Recruiting

Wed, 13 Nov 2019 12:00:00 EST

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

Conditions:   Soft Tissue Sarcoma;   Mesothelioma
Intervention:   Drug: Azacitidine In Combination With Temozolomide
Sponsors:   Columbia University;   Schering-Plough;   Celgene Corporation
Unknown status

Thu, 06 Mar 2008 12:00:00 EST

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Leukemia;   Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Entinostat
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 10 Jan 2005 12:00:00 EST

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Condition:   Leukemia, Myeloid
Interventions:   Drug: CC-90011;   Drug: Venetoclax;   Drug: Azacitidine
Sponsor:   Celgene
Not yet recruiting

Wed, 10 Feb 2021 12:00:00 EST

Azacitidine and CAPOX in Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Azacitidine;   Drug: Capecitabine;   Drug: Oxaliplatin;   Drug: Azacitidine MTD
Sponsors:   M.D. Anderson Cancer Center;   Celgene
Completed

Thu, 02 Sep 2010 12:00:00 EDT

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

Conditions:   Acute Myeloid Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin Lymphoma
Interventions:   Drug: FT-1101;   Drug: Azacitidine
Sponsor:   Forma Therapeutics, Inc.
Completed

Mon, 07 Sep 2015 12:00:00 EDT

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Beta Erythropoietin
Sponsors:   PETHEMA Foundation;   Roche Pharma AG;   Celgene Corporation
Terminated

Tue, 03 Jul 2007 12:00:00 EDT

Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   High Risk Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Tosedostat
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Terminated

Tue, 10 Jul 2012 12:00:00 EDT

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions:   FLT3 Gene Mutation Negative;   FLT3 Internal Tandem Duplication Positive;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelomonocytic Leukemia;   Refractory Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Other: Pharmacodynamic Study;   Drug: Quizartinib
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Thu, 04 Jul 2013 12:00:00 EDT

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: G-CSF;   Drug: Plerixafor;   Drug: Azacitidine
Sponsor:   Washington University School of Medicine
Completed

Tue, 09 Feb 2010 12:00:00 EST

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia, Adult
Intervention:   Drug: ADI-PEG 20
Sponsor:   Polaris Group
Not yet recruiting

Thu, 12 Aug 2021 12:00:00 EDT

Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer

Conditions:   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions:   Drug: entinostat;   Drug: azacitidine;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 16 Apr 2010 12:00:00 EDT

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Pracinostat;   Drug: Placebos;   Drug: Azacitidine
Sponsors:   Helsinn Healthcare SA;   Clinipace Worldwide
Terminated

Fri, 12 May 2017 12:00:00 EDT

A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   AML;   MDS;   CMML
Interventions:   Drug: CFI-400945;   Drug: Azacitidine;   Drug: Decitabine
Sponsor:   Treadwell Therapeutics, Inc
Recruiting

Fri, 29 Jan 2021 12:00:00 EST

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Conditions:   Acute Myeloid Leukemia;   Recurrent Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Drug: Venetoclax
Sponsors:   Brian Jonas;   AbbVie;   National Cancer Institute (NCI)
Not yet recruiting

Fri, 28 May 2021 12:00:00 EDT

Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia

Condition:   Leukemia
Interventions:   Drug: azacitidine;   Other: laboratory biomarker analysis
Sponsor:   University of Leeds
Completed

Fri, 05 Nov 2010 12:00:00 EDT

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: arsenic trioxide;   Drug: azacitidine
Sponsors:   Jonsson Comprehensive Cancer Center;   CTI BioPharma;   Celgene Corporation
Terminated

Thu, 06 Oct 2005 12:00:00 EDT

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   Blasts 20-30 Percent of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   IDH2 Gene Mutation;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory High Risk Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Enasidenib;   Other: Quality-of-Life Assessment
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Celgene
Active, not recruiting

Tue, 26 Dec 2017 12:00:00 EST

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Conditions:   Chronic Myelomonocytic Leukemia;   Chronic Myelomonocytic Leukemia-1;   Chronic Myelomonocytic Leukemia-2;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2
Interventions:   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Vorinostat
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Wed, 01 Feb 2012 12:00:00 EST

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Conditions:   Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions:   Drug: CC-486;   Drug: Vidaza
Sponsor:   Celgene
Completed

Fri, 22 Aug 2014 12:00:00 EDT

Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine Injection;   Drug: Nivolumab;   Drug: Relatlimab
Sponsor:   Ludwig-Maximilians - University of Munich
Recruiting

Fri, 04 Jun 2021 12:00:00 EDT

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Small Intestine Lymphoma;   T-cell Large Granular Lymphocyte Leukemia
Interventions:   Drug: azacitidine;   Drug: bortezomib;   Procedure: Correlative studies
Sponsors:   Pierluigi Porcu;   Millennium Pharmaceuticals, Inc.;   Celgene Corporation
Completed

Mon, 24 May 2010 12:00:00 EDT

Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride
Sponsor:   National Cancer Institute (NCI)
Terminated

Wed, 15 Dec 2010 12:00:00 EST

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Mixed Phenotype Acute Leukemia;   Juvenile Myelomonocytic Leukemia
Interventions:   Drug: Vorinostat;   Drug: Azacitidine Injection
Sponsor:   Johns Hopkins All Children's Hospital
Recruiting

Mon, 18 Feb 2019 12:00:00 EST

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia
Interventions:   Biological: DSP107;   Drug: Azacitidine;   Drug: Venetoclax
Sponsor:   Kahr Medical
Not yet recruiting

Wed, 23 Jun 2021 12:00:00 EDT

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Conditions:   Stem Cell Transplantation;   Leukemia
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Drug: Azacitidine;   Procedure: Stem Cell Transplant
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Celgene Corporation
Completed

Mon, 22 Dec 2008 12:00:00 EST

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome
Interventions:   Biological: MEDI4736 Evaluate MEDI4736 in MDS;   Drug: VIDAZA;   Biological: tremelimumab
Sponsor:   MedImmune LLC
Completed

Thu, 17 Apr 2014 12:00:00 EDT

Dose Escalation/ Expansion Trial of CA-4948 as Monotherapy and in Combination With Azacitidine or Venetoclax in Patients With AML or MDS

Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: CA-4948;   Drug: Azacitidine;   Drug: Venetoclax
Sponsor:   Curis, Inc.
Recruiting

Thu, 20 Feb 2020 12:00:00 EST

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Condition:   Peripheral T-cell Lymphoma
Interventions:   Drug: Sintilimab;   Drug: Chidamide;   Drug: Azacidine
Sponsor:   Peking University
Not yet recruiting

Mon, 12 Aug 2019 12:00:00 EDT

Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes

Condition:   MDS
Interventions:   Drug: Azacitidine;   Drug: Azacitidine associated with Valproic acid;   Drug: Azacitidine associated with Lenalidomide;   Drug: Azacitidine associated with Idarubicine
Sponsor:   Assistance Publique - Hôpitaux de Paris
Unknown status

Wed, 27 Apr 2011 12:00:00 EDT

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Condition:   Thrombocytopaenia
Interventions:   Drug: Eltrombopag;   Drug: Azacitidine;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Terminated

Mon, 09 Jun 2014 12:00:00 EDT

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine;   Drug: Idarubicin;   Drug: Daunorubicin;   Drug: Liposomal daunorubicin and cytarabine;   Drug: Venetoclax;   Drug: Azacitidine
Sponsors:   Massachusetts General Hospital;   AbbVie
Recruiting

Wed, 17 Mar 2021 12:00:00 EDT

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions:   Drug: vorinostat;   Drug: gemtuzumab ozogamicin;   Drug: azacitidine
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 08 May 2009 12:00:00 EDT

A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer

Conditions:   Advanced or Metastatic Solid Tumors;   Advanced or Metastatic Breast Cancer
Interventions:   Drug: Azacitidine (Vidaza);   Drug: Nab-paclitaxel (Abraxane)
Sponsors:   University of Utah;   Celgene Corporation
Completed

Mon, 08 Sep 2008 12:00:00 EDT

Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

Condition:   MDS-EB
Interventions:   Drug: Azacitidine;   Drug: CAG Protocol
Sponsor:   Fujian Medical University
Recruiting

Thu, 02 Jan 2020 12:00:00 EST

Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Pracinostat;   Drug: Azacitidine
Sponsor:   Helsinn Healthcare SA
Completed

Wed, 31 Jul 2013 12:00:00 EDT

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

Conditions:   Leukemia;   Myelodysplastic Syndrome;   Recurrent Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Fri, 21 Aug 2015 12:00:00 EDT

Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia

Condition:   Acute Myelogenous Leukemia
Interventions:   Drug: Azacitidine;   Drug: Venetoclax;   Drug: Pevonedistat
Sponsor:   Medical College of Wisconsin
Active, not recruiting

Thu, 21 Nov 2019 12:00:00 EST

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Ibrutinib;   Drug: Ibrutinib + LD-AraC;   Drug: Ibrutinib+Azacitidine
Sponsor:   Pharmacyclics LLC.
Terminated

Fri, 30 Jan 2015 12:00:00 EST

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: arsenic trioxide;   Drug: azacitidine
Sponsor:   Medical University of South Carolina
Terminated

Mon, 11 Jul 2005 12:00:00 EDT

A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.

Conditions:   Hematologic Neoplasm;   Neoplasms
Intervention:   Drug: CC-486
Sponsor:   Celgene
Active, not recruiting

Fri, 10 Jul 2015 12:00:00 EDT

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Condition:   Leukemia
Interventions:   Drug: Pacritinib;   Drug: 5-azacitidine;   Drug: Decitabine
Sponsors:   M.D. Anderson Cancer Center;   CTI BioPharma
Terminated

Thu, 11 Jun 2015 12:00:00 EDT

Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: amifostine trihydrate;   Drug: azacitidine
Sponsors:   University of Michigan Rogel Cancer Center;   National Cancer Institute (NCI)
Completed

Tue, 16 Dec 2003 12:00:00 EST

Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)

Condition:   High-risk MDS
Interventions:   Drug: Azacitidine;   Drug: Standard Chemotherapy;   Procedure: Allogeneic stem cell transplantation
Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto
Not yet recruiting

Tue, 03 Dec 2019 12:00:00 EST

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphocytic Leukemia
Interventions:   Drug: Fludarabine;   Radiation: Fractionated total body irradiation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Drug: Melphalan;   Drug: Granulocyte-colony stimulating factor;   Procedure: Stem cell transplant;   Drug: Azacitidine
Sponsor:   Washington University School of Medicine
Terminated

Mon, 25 Apr 2016 12:00:00 EDT

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

Conditions:   Leukemia;   Lung Cancer;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Prostate Cancer
Interventions:   Drug: azacitidine;   Drug: sodium phenylbutyrate
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
Completed

Fri, 29 Aug 2003 12:00:00 EDT

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

Conditions:   Recurrent Melanoma;   Recurrent Renal Cell Cancer;   Stage III Melanoma;   Stage IV Melanoma;   Stage IV Renal Cell Cancer
Interventions:   Biological: recombinant interferon alfa-2b;   Drug: amifostine/azacitidine
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 22 Sep 2005 12:00:00 EDT

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Condition:   Refractory Multiple Myeloma
Interventions:   Drug: azacitidine;   Drug: lenalidomide;   Drug: dexamethasone;   Other: DNA methylation analysis;   Other: gene expression analysis;   Other: bone marrow aspiration;   Other: immunohistochemistry staining method;   Other: reverse transcriptase-polymerase chain reaction;   Other: flow cytometry
Sponsor:   Case Comprehensive Cancer Center
Completed

Fri, 02 Jul 2010 12:00:00 EDT

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: azacitidine;   Drug: sodium phenylbutyrate
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI)
Completed

Mon, 27 Jan 2003 12:00:00 EST

Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions:   Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 29 Nov 2010 12:00:00 EST

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: Milademetan;   Drug: AZA
Sponsor:   Daiichi Sankyo, Inc.
Terminated

Thu, 18 Dec 2014 12:00:00 EST

Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer

Conditions:   Esophageal Cancer;   Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Interventions:   Drug: Azacitidine;   Drug: Oxaliplatin;   Drug: Epirubicin;   Drug: Capecitabine
Sponsors:   Weill Medical College of Cornell University;   Celgene Corporation
Completed

Fri, 01 Jul 2011 12:00:00 EDT

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: 33A;   Drug: placebo;   Drug: azacitidine;   Drug: decitabine
Sponsor:   Seagen Inc.
Terminated

Mon, 30 May 2016 12:00:00 EDT

Safety and Performance Evaluation of the Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions

Condition:   Skin Neoplasms
Intervention:   Device: AC5 Topical Hemostatic Device
Sponsor:   ARCH Therapuetics
Completed

Wed, 09 Mar 2016 12:00:00 EST

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Cladribine;   Drug: Cytarabine;   Drug: Venetoclax
Sponsor:   M.D. Anderson Cancer Center
Recruiting

Fri, 13 Jul 2018 12:00:00 EDT

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: Cusatuzumab;   Drug: Azacitidine;   Drug: Venetoclax
Sponsors:   Janssen Research & Development, LLC;   argenx
Active, not recruiting

Tue, 05 Nov 2019 12:00:00 EST

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

Conditions:   Adult T-cell Leukemia/Lymphoma;   Extranodal NK-/T-cell Lymphoma, Nasal Type;   Enteropathy-Associated T-Cell Lymphoma;   Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma
Interventions:   Drug: CC-486 (5-azacitidine);   Drug: Duvelisib;   Drug: Romidepsin;   Drug: Doxorubicin
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting

Mon, 23 Nov 2020 12:00:00 EST

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Fludarabine Phosphate;   Drug: Methotrexate;   Drug: Pevonedistat;   Drug: Therapeutic Hydrocortisone
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group
Active, not recruiting

Wed, 23 Jan 2019 12:00:00 EST

Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine

Condition:   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Cytarabine;   Drug: Idarubicin;   Drug: Etoposide;   Drug: Azacitidine;   Drug: Lenograstim
Sponsor:   University of Ulm
Completed

Thu, 12 Aug 2010 12:00:00 EDT

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Condition:   Myeloid Malignancy
Interventions:   Drug: APR-246;   Drug: Venetoclax;   Drug: Azacitidine
Sponsor:   Aprea Therapeutics
Active, not recruiting

Thu, 02 Jan 2020 12:00:00 EST

Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

Condition:   AML
Interventions:   Drug: Venetoclax 100 MG;   Drug: Itraconazole capsule;   Drug: Azacitidine Injection
Sponsor:   Hospital Universitario Dr. Jose E. Gonzalez
Recruiting

Fri, 17 Sep 2021 12:00:00 EDT

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Adult Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Recombinant EphB4-HSA Fusion Protein
Sponsors:   University of Southern California;   National Cancer Institute (NCI)
Terminated

Wed, 10 May 2017 12:00:00 EDT

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes (MDS)
Interventions:   Drug: APG-115;   Drug: Azacitidine;   Drug: Cytarabine
Sponsors:   Ascentage Pharma Group Inc.;   Suzhou Yasheng Pharmaceutical Co., Ltd.
Recruiting

Wed, 19 Feb 2020 12:00:00 EST

Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma

Condition:   Melanoma (Skin)
Interventions:   Biological: recombinant interferon alfa-2b;   Drug: azacitidine
Sponsors:   University of California, San Diego;   National Cancer Institute (NCI)
Completed

Fri, 10 Nov 2006 12:00:00 EST

Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: intensive chemotherapy;   Drug: Azacitidine
Sponsor:   University Hospital, Toulouse
Active, not recruiting

Fri, 15 Sep 2017 12:00:00 EDT

ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia
Interventions:   Drug: ABT-348;   Drug: ABT-348 and azacitidine
Sponsor:   AbbVie (prior sponsor, Abbott)
Completed

Mon, 26 Apr 2010 12:00:00 EDT

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Conditions:   Acute Myelogenous Leukemia;   Myelogenous Leukemia;   Treatment Naive AML
Interventions:   Drug: Posaconazole;   Drug: ABT-199;   Drug: Decitabine;   Drug: Azacitidine
Sponsors:   AbbVie;   Genentech, Inc.
Active, not recruiting

Wed, 30 Jul 2014 12:00:00 EDT

A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Conditions:   Cutaneous T-Cell Lymphoma;   Mature T-cell Malignancies;   Peripheral T-Cell Lymphoma;   Relapsed/ Refractory T-cell Malignancies
Interventions:   Drug: Romidepsin;   Drug: Lenalidomide;   Drug: CC-486 (5-azacitidine);   Drug: Dexamethasone
Sponsor:   National Cancer Institute (NCI)
Suspended

Thu, 25 Jun 2020 12:00:00 EDT

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Condition:   Acute Myeloid Leukemia
Interventions:   Biological: Sabatolimab;   Drug: Azacitidine
Sponsor:   Novartis Pharmaceuticals
Recruiting

Tue, 10 Nov 2020 12:00:00 EST

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: 5-Azacytidine;   Drug: Valproic Acid;   Drug: ATRA
Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto
Completed

Mon, 26 Feb 2007 12:00:00 EST

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Conditions:   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Drug: Salsalate;   Drug: Venetoclax
Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
Recruiting

Thu, 31 Oct 2019 12:00:00 EDT

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Condition:   Neoplasms
Interventions:   Drug: GSK3326595;   Drug: 5-Azacitidine
Sponsor:   GlaxoSmithKline
Recruiting

Fri, 03 Aug 2018 12:00:00 EDT

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood
Interventions:   Drug: Azacytidine;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Intrathecal (IT) Cytarabine;   Drug: Intrathecal Methotrexate (IT MTX)
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Gateway for Cancer Research
Completed

Thu, 23 May 2013 12:00:00 EDT

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Condition:   Breast Neoplasms
Interventions:   Drug: CC-486;   Drug: Fulvestrant
Sponsor:   Celgene
Terminated

Fri, 27 Feb 2015 12:00:00 EST

EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2

Conditions:   AML, Adult;   Myelodysplastic Syndromes
Intervention:   Biological: NKR-2 CAR-T Cells
Sponsor:   Celyad Oncology SA
Withdrawn

Thu, 02 Aug 2018 12:00:00 EDT

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

Conditions:   Prostate Cancer;   Pain
Interventions:   Drug: Azacitidine;   Drug: Docetaxel;   Drug: Prednisone;   Genetic: GADD45α methylation and expression analysis;   Drug: Pegfilgrastim;   Drug: Filgrastim
Sponsor:   University of Miami
Terminated

Thu, 19 Jul 2007 12:00:00 EDT

Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: low-dose Azacitidine;   Drug: Pioglitazone;   Drug: ATRA;   Drug: standard-dose AZA
Sponsors:   University Hospital Regensburg;   Anticancer Fund, Belgium;   Celgene
Terminated

Mon, 24 Oct 2016 12:00:00 EDT

Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Venetoclax;   Drug: Azacitidine;   Drug: Cladribine;   Drug: Cytarabine;   Drug: Idarubicin
Sponsor:   LanZhou University
Not yet recruiting

Wed, 22 Sep 2021 12:00:00 EDT

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)

Condition:   PTCL
Interventions:   Drug: Azacytidine;   Drug: Romidepsin;   Drug: Belinostat;   Drug: Pralatrexate;   Drug: Gemcitabine
Sponsors:   University of Virginia;   Celgene
Recruiting

Wed, 10 Feb 2021 12:00:00 EST

Treatment of Acute Leukemia Relapse After Allotransplantation

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.
Sponsor:   University of Bergen
Unknown status

Wed, 08 Jun 2011 12:00:00 EDT

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: Azacitidine Injection [Vidaza]
Sponsors:   Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias;   Hospital Son Llatzer;   Germans Trias i Pujol Hospital;   Celgene Corporation
Recruiting

Mon, 26 Oct 2020 12:00:00 EDT

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Condition:   AML, Adult
Intervention:   Drug: APG 2575 ramp up arm
Sponsor:   Ascentage Pharma Group Inc.
Not yet recruiting

Fri, 16 Jul 2021 12:00:00 EDT

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

Conditions:   Non-Small Cell Lung Cancer;   Epigenetic Therapy
Interventions:   Drug: Azacitidine;   Drug: Entinostat;   Drug: Nivolumab
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Rising Tide Foundation;   Stand Up To Cancer;   Bristol-Myers Squibb;   Celgene;   Syndax Pharmaceuticals, Inc.;   Rhone-Poulenc Rorer
Recruiting

Mon, 26 Aug 2013 12:00:00 EDT

Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

Condition:   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: midostaurin;   Drug: azacitidine;   Other: bone marrow aspiration;   Other: mutation analysis;   Other: Pharmacokinetic study
Sponsors:   Brenda Cooper, MD;   National Cancer Institute (NCI)
Completed

Fri, 26 Mar 2010 12:00:00 EDT

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2
Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin;   Biological: Nivolumab
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Tue, 28 Mar 2017 12:00:00 EDT

Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Biological: Magrolimab;   Drug: Venetoclax;   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Idarubicin;   Drug: Steroidal Eye Drops
Sponsor:   Gilead Sciences
Recruiting

Wed, 03 Mar 2021 12:00:00 EST

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

Conditions:   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular
Interventions:   Drug: Oral Azacitidine;   Drug: Rituximab;   Drug: cyclophosphamide;   Drug: Vincristine;   Drug: Prednisone
Sponsor:   Celgene
Completed

Thu, 22 Jan 2015 12:00:00 EST

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

Conditions:   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: MLN4924;   Drug: Azacitidine
Sponsor:   Millennium Pharmaceuticals, Inc.
Completed

Mon, 01 Jun 2009 12:00:00 EDT

Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)

Conditions:   Myelodysplastic Syndrome;   Thrombocytopenia
Intervention:   Drug: Eltrombopag
Sponsors:   Nordic MDS Group;   GlaxoSmithKline
Completed

Tue, 29 Nov 2011 12:00:00 EST

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

Conditions:   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions:   Drug: azacitidine;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Genetic: nucleic acid sequencing;   Procedure: therapeutic conventional surgery
Sponsors:   University of Southern California;   National Cancer Institute (NCI)
Withdrawn

Wed, 09 Feb 2011 12:00:00 EST

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Conditions:   Solid Tumors;   Advanced Malignancies;   Metastatic Cancer
Interventions:   Drug: Azacitidine;   Drug: Pembrolizumab;   Drug: Epacadostat;   Drug: INCB057643;   Drug: INCB059872
Sponsor:   Incyte Corporation
Terminated

Wed, 09 Nov 2016 12:00:00 EST

A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: SY-1425 (tamibarotene);   Drug: azacitidine;   Drug: Daratumumab
Sponsor:   Syros Pharmaceuticals
Active, not recruiting

Tue, 21 Jun 2016 12:00:00 EDT

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Mon, 11 Jul 2016 12:00:00 EDT

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Condition:   Lymphoma
Interventions:   Drug: Busulfan;   Drug: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine;   Drug: Belinostat;   Drug: Azacitidine;   Drug: Gemcitabine;   Drug: Melphalan;   Procedure: Stem Cell Transplant
Sponsor:   M.D. Anderson Cancer Center
Withdrawn

Tue, 08 Mar 2016 12:00:00 EST

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Conditions:   Leukemia, Myeloid, Acute;   De Novo;   Age More 60yr
Interventions:   Drug: Azacitidine;   Drug: Venetoclax;   Drug: Quizartinib;   Drug: Cytarabine
Sponsor:   PETHEMA Foundation
Recruiting

Tue, 29 Dec 2020 12:00:00 EST

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: CC-486;   Drug: Venetoclax
Sponsors:   Celgene;   AbbVie
Not yet recruiting

Fri, 14 May 2021 12:00:00 EDT

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine, Abraxane, Gemcitabine)

Condition:   Pancreatic Cancer
Interventions:   Drug: oral azacitidine;   Other: Observation;   Drug: First-line chemotherapy after recurrence
Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting

Fri, 03 May 2013 12:00:00 EDT

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: glasdegib;   Drug: daunorubicin + cytarabine;   Drug: azacitidine;   Drug: Placebo;   Drug: cytarabine;   Procedure: HSCT
Sponsor:   Pfizer
Active, not recruiting

Wed, 31 Jan 2018 12:00:00 EST

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome
Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Other: Quality-of-Life Assessment
Sponsor:   Fred Hutchinson Cancer Research Center
Recruiting

Mon, 18 Mar 2013 12:00:00 EDT

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

Condition:   Diffuse Large B Cell Lymphoma
Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: vincristine;   Drug: doxorubicin;   Drug: prednisone;   Drug: azacytidine
Sponsors:   Weill Medical College of Cornell University;   Celgene
Completed

Fri, 30 Oct 2009 12:00:00 EDT

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Patients.

Condition:   Acute Myeloid Leukaemia
Interventions:   Drug: AZD2811;   Drug: Azacitidine;   Drug: Venetoclax
Sponsor:   AstraZeneca
Terminated

Fri, 14 Jul 2017 12:00:00 EDT

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Condition:   Nasopharyngeal Neoplasms
Intervention:   Drug: CC-486
Sponsor:   Celgene
Completed

Tue, 21 Oct 2014 12:00:00 EDT

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host Disease

Condition:   Graft Versus Host Disease
Interventions:   Drug: Cyclophospahmide and Sirolimus;   Drug: Low dose IL-2, Cyclophosphamide and Sirolimus;   Drug: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
Sponsor:   Hackensack Meridian Health
Completed

Mon, 17 Oct 2011 12:00:00 EDT

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Azacitadine;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Lenograstim;   Drug: Filgastrim
Sponsors:   PETHEMA Foundation;   Dynamic Solutions
Completed

Thu, 18 Dec 2014 12:00:00 EST

Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndromes
Intervention:  
Sponsor:   Seoul National University Hospital
Completed

Wed, 03 Aug 2011 12:00:00 EDT

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions:   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Biological: Anti-OX40 Agonist Monoclonal Antibody PF-04518600;   Drug: Avelumab;   Drug: Azacitidine;   Drug: Gemtuzumab Ozogamicin;   Drug: Glasdegib;   Drug: Glasdegib Maleate;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Thu, 04 Jan 2018 12:00:00 EST

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Conditions:   Ann Arbor Stage III Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Grade 3b Follicular Lymphoma;   HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Intravascular Large B-Cell Lymphoma;   Lymphoplasmacytic Lymphoma;   Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma;   Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Oral Azacitidine;   Drug: Prednisone;   Other: Questionnaire Administration;   Biological: Rituximab;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting

Tue, 16 Mar 2021 12:00:00 EDT

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

Conditions:   Myelodysplastic Syndrome;   MDS
Interventions:   Drug: pracinostat;   Drug: Azacitidine;   Drug: Decitabine
Sponsor:   Helsinn Healthcare SA
Completed

Mon, 25 Nov 2013 12:00:00 EST

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

Conditions:   Advanced Cancers;   Lymphoma
Interventions:   Drug: Azacitidine;   Drug: Vorinostat;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Drug: Dexamethasone;   Other: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine;   Drug: Rituximab
Sponsor:   M.D. Anderson Cancer Center
Completed

Thu, 14 Nov 2013 12:00:00 EST

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Conditions:   Indolent B-Cell Non-Hodgkin Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hairy Cell Leukemia;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Mucosa-Associated Lymphoid Tissue Lymphoma;   Refractory Follicular Lymphoma;   Refractory Hairy Cell Leukemia;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Small Lymphocytic Lymphoma
Interventions:   Drug: Lenalidomide;   Biological: Obinutuzumab;   Drug: Oral Azacitidine
Sponsors:   Joseph Tuscano;   National Cancer Institute (NCI);   Celgene
Recruiting

Thu, 08 Oct 2020 12:00:00 EDT

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

Condition:   Head and Neck Cancer
Interventions:   Drug: azacitidine;   Drug: liothyronine sodium;   Radiation: iodine I 131
Sponsors:   Lucille P. Markey Cancer Center at University of Kentucky;   National Cancer Institute (NCI)
Completed

Fri, 04 Jun 2004 12:00:00 EDT

A Study of Pevonedistat in Adult East Asian Participants

Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Interventions:   Drug: Pevonedistat 25 mg/m^2;   Drug: Pevonedistat 44 mg/m^2;   Drug: Pevonedistat 10 mg/m^2;   Drug: Pevonedistat 20 mg/m^2;   Drug: Azacitidine 75 mg/m^2
Sponsor:   Millennium Pharmaceuticals, Inc.
Active, not recruiting

Wed, 25 May 2016 12:00:00 EDT

Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: Venetoclax
Sponsor:   Helsinki University Central Hospital
Recruiting

Wed, 12 Feb 2020 12:00:00 EST

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

Conditions:   Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Acute Myeloid Leukemia (AML)
Intervention:   Drug: Panobinostat
Sponsor:   Novartis Pharmaceuticals
Completed

Thu, 07 Jun 2012 12:00:00 EDT

TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Drug: Dubermatinib
Sponsors:   Bhavana Bhatnagar;   Sumitomo Pharmaceuticals America
Recruiting

Wed, 19 Aug 2020 12:00:00 EDT

An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands

Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Myeloid, Acute
Intervention:  
Sponsor:   Celgene
Completed

Wed, 07 Sep 2016 12:00:00 EDT

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Conditions:   Acute Myeloid Leukemia, Adult;   Hypomethylating Agents;   Venetoclax
Intervention:   Drug: Venetoclax
Sponsor:   Ospedale Maggiore Di Trieste
Recruiting

Wed, 01 Jul 2020 12:00:00 EDT

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome
Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Azacitidine;   Drug: Busulfan;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Other: Pharmacological Study;   Drug: Tacrolimus
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Fri, 23 Jul 2010 12:00:00 EDT

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
Interventions:   Drug: Azacitidine;   Biological: Pembrolizumab;   Drug: Venetoclax
Sponsor:   National Cancer Institute (NCI)
Recruiting

Wed, 26 Feb 2020 12:00:00 EST

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Conditions:   Hematopoietic and Lymphoid Cell Neoplasm;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelomonocytic Leukemia;   Refractory Myelodysplastic Syndrome
Interventions:   Drug: DS-1594b;   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Biological: Filgrastim;   Drug: Leucovorin;   Drug: Mesna;   Drug: Methotrexate;   Drug: Posaconazole;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine;   Drug: Voriconazole
Sponsor:   M.D. Anderson Cancer Center
Recruiting

Fri, 12 Feb 2021 12:00:00 EST

Study of INCB053914 in Subjects With Advanced Malignancies

Condition:   Solid Tumors
Interventions:   Drug: INCB053914;   Drug: I-DAC (Intermediate dose cytarabine);   Drug: Azacitidine;   Drug: Ruxolitinib
Sponsor:   Incyte Corporation
Completed

Tue, 27 Oct 2015 12:00:00 EDT

Expanded Access for CC-486

Condition:   Acute Myelogenous Leukemia (AML)
Intervention:   Drug: CC-486
Sponsor:   Celgene
Approved for marketing

Mon, 29 Oct 2018 12:00:00 EDT

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Conditions:   Leukemia;   Leukemia, Myeloid;   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes;   Preleukemia;   Bone Marrow Diseases;   Hematologic Diseases;   Chronic Myelomonocytic Leukemia
Interventions:   Drug: Decitabine;   Drug: PDR001;   Drug: MBG453;   Drug: Azacitidine
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting

Tue, 28 Feb 2017 12:00:00 EST

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions:   Drug: Azacitidine;   Drug: Docetaxel;   Drug: Entinostat;   Drug: Gemcitabine Hydrochloride;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Pemetrexed Disodium
Sponsor:   National Cancer Institute (NCI)
Terminated

Thu, 05 Sep 2013 12:00:00 EDT

ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Vesanoid (ATRA);   Drug: AZACITIDINE (VIDAZA);   Drug: CYTARABINE
Sponsors:   Acute Leukemia French Association;   Assistance Publique - Hôpitaux de Paris
Withdrawn

Thu, 11 Feb 2010 12:00:00 EST

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Interventions:   Drug: ARGX-110;   Drug: AZA
Sponsors:   Janssen Research & Development, LLC;   argenx
Active, not recruiting

Wed, 25 Jan 2017 12:00:00 EST

Precision Therapy Versus Standard Therapy in AML and MDS in Elderly

Conditions:   AML, Adult;   MDS
Interventions:   Drug: Standard therapy;   Drug: Precision therapy
Sponsor:   University Hospital, Akershus
Recruiting

Fri, 27 Aug 2021 12:00:00 EDT

Study of the Glutaminase Inhibitor CB-839 in Leukemia

Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL)
Interventions:   Drug: CB-839;   Drug: CB-Aza
Sponsor:   Calithera Biosciences, Inc
Completed

Wed, 26 Feb 2014 12:00:00 EST

Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma

Condition:   Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Interventions:   Drug: tislelizumab, azacytidine, lenalidomide;   Drug: tislelizumab, etoposide, pegaspargase
Sponsor:   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Recruiting

Tue, 28 Sep 2021 12:00:00 EDT

Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: pembrolizumab;   Drug: Azacitadine
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Merck Sharp & Dohme Corp.
Active, not recruiting

Wed, 27 Jul 2016 12:00:00 EDT

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: CC-90009;   Drug: Venetoclax;   Drug: Azacitidine;   Drug: Gilteritinib
Sponsors:   Celgene;   AbbVie
Recruiting

Tue, 07 Apr 2020 12:00:00 EDT

FLT-PET Imaging for MDS

Conditions:   AML;   MDS
Intervention:   Procedure: FLT-PET scans
Sponsor:   University of Wisconsin, Madison
Terminated

Fri, 17 Feb 2012 12:00:00 EST

Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

Conditions:   MDS;   AML
Interventions:   Drug: CPX-351;   Drug: Daunorubicin;   Drug: Cytarabine;   Drug: Azacitidine
Sponsor:   GWT-TUD GmbH
Recruiting

Mon, 19 Aug 2019 12:00:00 EDT

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Condition:   Previously Untreated Peripheral T-cell Lymphoma
Interventions:   Drug: CC-486 Administration;   Drug: CHOP Administration
Sponsors:   Weill Medical College of Cornell University;   Celgene Corporation
Active, not recruiting

Thu, 31 May 2018 12:00:00 EDT

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: CC-486;   Drug: Pembrolizumab;   Drug: Placebo
Sponsor:   Celgene
Active, not recruiting

Fri, 11 Sep 2015 12:00:00 EDT

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory AML

Condition:   Relapsed/Refractory Acute Myeloid Leukaemia
Interventions:   Drug: APG-2575;   Drug: reduced-dose HHT;   Drug: standard-dose HHT;   Drug: Azacitidine
Sponsors:   Ascentage Pharma Group Inc.;   Suzhou Yasheng Pharmaceutical Co., Ltd.
Recruiting

Thu, 06 Aug 2020 12:00:00 EDT

High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)

Condition:   High-risk Myelodysplastic Syndromes With Excess Blasts
Intervention:   Diagnostic Test: Myelogram
Sponsors:   Central Hospital, Nancy, France;   Inserm U954 - N-GERE (Nutrition, Genetics and Exposition to Environmental Risk)
Recruiting

Fri, 14 Jul 2017 12:00:00 EDT

Allogenic NK Cell Transfusion Azacitidine MDS-EB

Condition:   MDS-EB
Intervention:   Biological: Allogeneic NK cell regimen group
Sponsor:   The Second Hospital of Shandong University
Not yet recruiting

Thu, 22 Oct 2020 12:00:00 EDT

Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients

Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
Intervention:   Drug: Levofloxacin
Sponsor:   Centre Henri Becquerel
Recruiting

Fri, 20 Jul 2018 12:00:00 EDT

A Study of BGB-11417 in Participants With Myeloid Malignancies

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasm
Interventions:   Drug: BGB-11417;   Drug: Azacitidine;   Drug: Posaconazole
Sponsor:   BeiGene
Recruiting

Thu, 25 Feb 2021 12:00:00 EST

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Conditions:   Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Chronic Myelomonocytic Leukemia;   Cytopenia
Intervention:   Drug: rigosertib sodium
Sponsor:   Onconova Therapeutics, Inc.
Completed

Mon, 26 Aug 2013 12:00:00 EDT

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Conditions:   Multiple Myeloma;   Acute Myeloid Leukemia;   Non-Hodgkins Lymphoma;   Myelodysplastic Syndrome;   AML;   MDS;   NHL
Interventions:   Drug: AMG 397;   Drug: Dexamethasone;   Drug: Azacitidine
Sponsor:   Amgen
Terminated

Wed, 14 Mar 2018 12:00:00 EDT

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN

Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML);   MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable);   Hematopoietic Stem Cell Transplant
Interventions:   Drug: Venetoclax;   Drug: Fludarabine;   Drug: Busulfan;   Drug: Azacitidine
Sponsors:   Jacqueline Garcia, MD;   National Institutes of Health (NIH)
Recruiting

Fri, 03 Aug 2018 12:00:00 EDT

Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients

Condition:   Prevention
Interventions:   Drug: Levofloxacin;   Drug: Placebo Oral Tablet
Sponsor:   Sheba Medical Center
Unknown status

Mon, 05 Dec 2016 12:00:00 EST

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Condition:   Myelodysplastic Syndrome (MDS)
Interventions:   Drug: MBG453;   Drug: Azacitidine;   Drug: Decitabine;   Drug: INQOVI (oral decitabine)
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting

Fri, 07 May 2021 12:00:00 EDT

Acute Myeloid Leukemia Real World Treatment Patterns

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: azacitidine;   Drug: venetoclax;   Drug: glasdegib
Sponsor:   Pfizer
Withdrawn

Sat, 18 Jan 2020 12:00:00 EST

A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

Condition:   Acute Myeloid Leukemia (AML)
Interventions:   Drug: SKLB1028;   Drug: Salvage Chemotherapy
Sponsor:   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Not yet recruiting

Wed, 20 Jan 2021 12:00:00 EST

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

Conditions:   Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia
Intervention:   Drug: Decitabine
Sponsors:   M.D. Anderson Cancer Center;   Eisai Inc.
Terminated

Wed, 08 Jun 2005 12:00:00 EDT

A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Conditions:   Cohort 1a and 1b: Glioma;   Cohort 1a and 1b: Glioblastoma Multiforme;   Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas);   Cohort 3a and 3b: Chondrosarcoma;   Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma;   Cohort 5a: Other Solid Tumors With IDH1 Mutations
Interventions:   Drug: FT-2102;   Drug: Azacitidine;   Biological: Nivolumab;   Drug: Gemcitabine and Cisplatin
Sponsor:   Forma Therapeutics, Inc.
Active, not recruiting

Wed, 26 Sep 2018 12:00:00 EDT

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: PF-04449913;   Drug: Low dose ARA-C (LDAC);   Drug: Daunorubicin;   Drug: Cytarabine;   Drug: Azacitidine;   Drug: LDAC
Sponsor:   Pfizer
Active, not recruiting

Fri, 17 Jan 2014 12:00:00 EST

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL

Conditions:   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions:   Biological: Antigen-Escalation Stage;   Biological: Dose-Escalation Stage;   Biological: azacytidine and multiTAA T cells Stage;   Biological: Pediatric multiTAA T cells Stage
Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital Research Institute;   National Cancer Institute (NCI)
Recruiting

Mon, 11 Apr 2011 12:00:00 EDT

Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

Condition:   Relapsed or Refractory Acute Myeloid Leukemia
Interventions:   Drug: Dexamethasone;   Drug: Amsacrine;   Drug: Cytarabine;   Drug: Azacitidine
Sponsor:   University Hospital, Toulouse
Recruiting

Wed, 05 Dec 2018 12:00:00 EST

A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

Condition:   Myelodysplastic Syndrome (MDS)
Intervention:   Drug: ASTX030
Sponsor:   Otsuka Pharmaceutical Co., Ltd.
Recruiting

Thu, 29 Oct 2020 12:00:00 EDT

Oral Arsenic Trioxide for NPM1-mutated AML

Condition:   NPMc+ AML
Intervention:   Drug: Oral Arsenic Trioxide Formulation
Sponsor:   The University of Hong Kong
Recruiting

Wed, 30 Dec 2020 12:00:00 EST

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Intervention:   Drug: CC-486
Sponsor:   Celgene
Completed

Fri, 19 Apr 2013 12:00:00 EDT

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Crenolanib besylate;   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Azacytidine;   Drug: Mitoxantrone;   Drug: Etoposide;   Drug: Fludarabine;   Drug: G-CSF
Sponsor:   Arog Pharmaceuticals, Inc.
Completed

Fri, 27 Mar 2015 12:00:00 EDT

Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: RAD001(Everolimus)
Sponsor:   Bayside Health
Unknown status

Mon, 17 Mar 2008 12:00:00 EDT

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

Conditions:   MDS;   Myelodysplastic Syndromes;   Thrombocytopenia
Interventions:   Drug: Placebo;   Biological: AMG 531 (Romiplostim);   Drug: Azacitidine;   Drug: Decitabine
Sponsor:   Amgen
Completed

Thu, 04 May 2006 12:00:00 EDT

GPS Compared With BAT in AML CR2/CR2p

Condition:   Acute Myeloid Leukemia
Interventions:   Biological: Galinpepimut-S;   Drug: Best Available Therapy
Sponsor:   Sellas Life Sciences Group
Recruiting

Sat, 18 Jan 2020 12:00:00 EST

New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Refractory Acute Leukemia;   Relapsed Adult AML
Interventions:   Drug: CAHAG regimen;   Drug: Placebo regimen
Sponsors:   The First Affiliated Hospital of Soochow University;   Ruijin Hospital;   West China Hospital;   Fujian Medical University Union Hospital;   The First Hospital of Jilin University;   Anhui Provincial Hospital;   Qilu Hospital of Shandong University;   The Affiliated Cancer Hospital of Zhengzhou University;   Shandong Provincial Hospital;   Nanfang Hospital of Southern Medical University;   First Affiliated Hospital of Harbin Medical University;   Xinqiao Hospital of Chongqing
Not yet recruiting

Tue, 31 Aug 2021 12:00:00 EDT

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: DFP-10917;   Drug: Cytarabine;   Drug: Azacitidine;   Drug: Decitabine;   Drug: Mitoxantrone;   Drug: Etoposide;   Drug: Fludarabine;   Drug: Idarubicin;   Drug: Venetoclax;   Drug: Cladribine
Sponsor:   Delta-Fly Pharma, Inc.
Recruiting

Wed, 24 Apr 2019 12:00:00 EDT

Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: decitabine (5-aza-2'deoxycytidine)
Sponsor:   Astex Pharmaceuticals, Inc.
Completed

Mon, 12 Aug 2002 12:00:00 EDT

Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure

Conditions:   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome
Intervention:   Drug: Decitabine
Sponsors:   King's College London;   King's College Hospital NHS Trust
Unknown status

Mon, 31 May 2010 12:00:00 EDT

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Condition:   Chronic Myelogenous Leukemia
Intervention:   Drug: decitabine (5-aza-2'deoxycytidine)
Sponsors:   Astex Pharmaceuticals, Inc.;   Eisai Inc.
Completed

Tue, 23 Jul 2002 12:00:00 EDT

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Condition:   Chronic Myelogenous Leukemia
Intervention:   Drug: decitabine (5-aza-2'deoxycytidine)
Sponsor:   Astex Pharmaceuticals, Inc.
Completed

Tue, 23 Jul 2002 12:00:00 EDT

Characterization of the Mechanisms of Resistance to Azacitidine

Condition:   Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia
Intervention:  
Sponsor:   Centre Hospitalier Universitaire de Nice
Unknown status

Tue, 28 Sep 2010 12:00:00 EDT

AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Conditions:   Relapsed or Refractory Multiple Myeloma;   Relapsed or Refractory Acute Myeloid Leukemia
Interventions:   Drug: AMG 176;   Drug: Azacitidine;   Drug: Itraconazole
Sponsor:   Amgen
Recruiting

Fri, 05 Feb 2016 12:00:00 EST

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes(MDS)
Intervention:   Drug: TJ011133
Sponsor:   I-Mab Biopharma Co. Ltd.
Recruiting

Tue, 17 Dec 2019 12:00:00 EST

A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies

Conditions:   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia
Interventions:   Drug: TTI-622;   Drug: Azacitidine;   Drug: Venetoclax;   Drug: Carfilzomib;   Drug: Dexamethasone
Sponsor:   Trillium Therapeutics Inc.
Recruiting

Mon, 21 May 2018 12:00:00 EDT

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

Conditions:   Myelodysplastic Syndrome;   Acute Myelogenous Leukemia
Intervention:   Drug: MGCD0103
Sponsor:   Mirati Therapeutics Inc.
Completed

Wed, 10 May 2006 12:00:00 EDT

A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

Condition:   MDS
Intervention:   Drug: SGI-110 administration
Sponsors:   Groupe Francophone des Myelodysplasies;   Astex Pharmaceuticals, Inc.
Completed

Wed, 23 Jul 2014 12:00:00 EDT

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Conditions:   Hematopoietic/Lymphoid Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: decitabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Terminated

Thu, 05 Aug 2004 12:00:00 EDT

Decitabine in Treating Patients With Advanced Solid Tumors

Conditions:   Male Breast Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Melanoma;   Stage III Melanoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: decitabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 27 Jan 2003 12:00:00 EST

Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   de Novo Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: decitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsor:   National Cancer Institute (NCI)
Terminated

Mon, 27 Jan 2003 12:00:00 EST

Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency

Condition:   N-Acetylneuraminic Acid Storage Disease
Intervention:   Other: Neu5Ac supplementation
Sponsors:   University of Lausanne;   University of Modena and Reggio Emilia
Completed

Mon, 04 Jun 2018 12:00:00 EDT

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

Conditions:   Neoplasms;   Solid Tumors
Intervention:   Drug: aza-TdC
Sponsor:   National Cancer Institute (NCI)
Recruiting

Fri, 08 Dec 2017 12:00:00 EST

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Conditions:   Leukemia, Myeloid;   Isocitrate Dehydrogenase
Interventions:   Drug: AG-221;   Other: BSC;   Drug: Azacitidine;   Drug: Low-dose cytarabine (LDAC);   Drug: Intermediate-dose cytarabine (IDAC)
Sponsor:   Celgene
Active, not recruiting

Fri, 16 Oct 2015 12:00:00 EDT

Window Trial 5-aza in HNSCC, T-tare

Condition:   Head and Neck Squamous Cell Carcinoma
Intervention:   Drug: 5-Azacitadine
Sponsor:   Yale University
Recruiting

Mon, 30 Jun 2014 12:00:00 EDT

Duvelisib in Combination With CC-486 in Lymphoid Malignancy

Conditions:   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Myeloma;   Lymphocytic Leukemia
Interventions:   Drug: CC-486;   Drug: Duvelisib
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Secura Bio, Inc.
Recruiting

Mon, 04 Oct 2021 12:00:00 EDT

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Condition:   Solid Tumors and Hematologic Malignancy
Interventions:   Drug: INCB059872;   Drug: all-trans retinoic acid (ATRA);   Drug: azacitidine;   Drug: nivolumab
Sponsor:   Incyte Corporation
Active, not recruiting

Fri, 18 Mar 2016 12:00:00 EDT

Combining Active and Passive DNA Hypomethylation

Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Interventions:   Dietary Supplement: Vitamin C;   Dietary Supplement: Placebo
Sponsors:   Kirsten Grønbæk;   Van Andel Research Institute;   Karolinska University Hospital;   Skane University Hospital;   Sahlgrenska University Hospital, Sweden;   Oslo University Hospital;   Helsinki University Central Hospital;   University of Southern California;   Imperial College London;   University of Copenhagen;   Zealand University Hospital;   Aalborg University Hospital;   Odense University Hospital;   Technical University of Denmark;   Aarhus University Hospital;   Norrland University Hospital;   Uppsala University Hospital
Recruiting

Thu, 27 Jun 2019 12:00:00 EDT

Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: CHG regimen;   Drug: 5-aza-deoxycytidine
Sponsor:   Xiao Li
Unknown status

Tue, 16 Aug 2011 12:00:00 EDT

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

Conditions:   Melanoma;   Melanoma, Uveal;   Head and Neck Cancer
Intervention:   Biological: Adoptive therapy with autologous MC2 TCR T cells
Sponsors:   Erasmus Medical Center;   Ludwig Institute for Cancer Research;   Dutch Cancer Society;   Stichting Coolsingel Rotterdam grant;   Jan Ivo Stichting grant
Recruiting

Thu, 28 Jan 2021 12:00:00 EST

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Relapsing Chronic Myelogenous Leukemia
Interventions:   Drug: imatinib mesylate;   Drug: decitabine;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 06 Feb 2003 12:00:00 EST

Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: Clofarabine
Sponsors:   Texas Oncology Cancer Center;   Genzyme, a Sanofi Company
Terminated

Wed, 18 Jun 2008 12:00:00 EDT

An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: Decitabine
Sponsor:   Johnson & Johnson Taiwan Ltd
Completed

Mon, 01 Sep 2008 12:00:00 EDT

Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia

Condition:   Thalassemia
Intervention:   Drug: Decitabine (USAN, INN)
Sponsors:   HealthCore-NERI;   National Heart, Lung, and Blood Institute (NHLBI)
Completed

Fri, 18 Apr 2008 12:00:00 EDT

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

Condition:   Epithelial Ovarian Cancer
Interventions:   Drug: CC-486;   Biological: Pembrolizumab
Sponsors:   Translational Research in Oncology;   Celgene
Completed

Wed, 14 Sep 2016 12:00:00 EDT

Non-interventional Study With Azacitidin (Vidaza®)

Conditions:   MDS;   AML;   CMMOL
Intervention:  
Sponsor:   iOMEDICO AG
Completed

Wed, 01 Sep 2010 12:00:00 EDT

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: nab-paclitaxel IV;   Drug: CC-486;   Drug: Duravalumab
Sponsor:   Celgene
Active, not recruiting

Fri, 26 Sep 2014 12:00:00 EDT

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

Condition:   Follicular Lymphoma
Interventions:   Drug: Venetoclax;   Drug: Obinutuzumab;   Drug: CC-486
Sponsor:   University of Chicago
Not yet recruiting

Mon, 25 Jan 2021 12:00:00 EST

Nivolumab With Chemotherapy in Refractory MDS

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Nivolumab;   Drug: Azacitidine;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: all trans retinoic acid;   Drug: Sildenafil;   Drug: Melphalan
Sponsor:   St. Petersburg State Pavlov Medical University
Terminated

Wed, 23 Aug 2017 12:00:00 EDT

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

Conditions:   Lung Cancer;   Non Small Cell Lung Carcinoma;   Hypermethylation
Interventions:   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Vidaza;   Procedure: Tumor Specimen for Methylation Analysis;   Procedure: Blood Sample for Methylation Analysis;   Drug: Vinorelbine;   Drug: Docetaxel;   Drug: Pemetrexed
Sponsor:   University of Miami
Completed

Mon, 27 Sep 2010 12:00:00 EDT

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Venetoclax;   Drug: Cytarabine;   Drug: Idarubicin;   Drug: Intrathecal Triple Therapy;   Drug: Azacitidine
Sponsors:   St. Jude Children's Research Hospital;   Gateway for Cancer Research
Recruiting

Wed, 21 Jun 2017 12:00:00 EDT

Comparative Study of Muc5ac and Muc2 Mucins in Tear Film Concentration in Surgical Treated Pterygia Patients

Condition:   Pterygium of Both Eyes
Intervention:   Procedure: Amniotic membrane transplantation
Sponsor:   Instituto de Oftalmología Fundación Conde de Valenciana
Completed

Wed, 13 May 2020 12:00:00 EDT

5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates

Condition:   Cancer
Intervention:   Drug: Decitabine and Pegylated Interferon-Alfa 2B
Sponsors:   Nevada Cancer Institute;   National Institutes of Health (NIH);   Schering-Plough
Terminated

Thu, 23 Apr 2009 12:00:00 EDT

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Biological: peginterferon alfa-2b;   Drug: decitabine;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Terminated

Thu, 19 Jun 2008 12:00:00 EDT

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Myeloid, Acute;   Renal Insufficiency;   Liver Disease;   Neoplasms
Interventions:   Drug: Azacitidine;   Drug: Pevonedistat;   Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting

Wed, 23 Jan 2019 12:00:00 EST

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Condition:   Melanoma
Interventions:   Drug: Decitabine;   Drug: Pegylated Interferon Alpha-2b
Sponsors:   M.D. Anderson Cancer Center;   Schering-Plough;   Eisai Inc.
Terminated

Fri, 14 Nov 2008 12:00:00 EST

Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Decitabine;   Drug: Interferon Alfa-2b
Sponsors:   M.D. Anderson Cancer Center;   Eisai Inc.
Terminated

Wed, 21 Nov 2007 12:00:00 EST

A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

Condition:   Acute Lymphocytic Leukemia
Intervention:   Drug: Decitabine
Sponsors:   M.D. Anderson Cancer Center;   Eisai Inc.
Completed

Fri, 07 Jul 2006 12:00:00 EDT

Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Conditions:   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Promyelocytic Leukemia (M3);   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: decitabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Terminated

Mon, 27 Jan 2003 12:00:00 EST

Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

Conditions:   Pancreas Cancer;   Pancreatic Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma
Interventions:   Drug: Romidepsin;   Drug: Azacitidine;   Drug: nab-Paclitaxel;   Drug: Gemcitabine;   Drug: Durvalumab;   Drug: Lenalidomide capsule
Sponsors:   GWT-TUD GmbH;   Celgene;   AstraZeneca
Recruiting

Thu, 06 Feb 2020 12:00:00 EST

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Entospletinib;   Drug: Daunorubicin;   Drug: Cytarabine;   Drug: Decitabine;   Drug: Azacitidine
Sponsor:   Gilead Sciences
Terminated

Thu, 22 Jan 2015 12:00:00 EST

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Condition:   Myelodysplastic Syndrome (MDS)
Intervention:   Drug: BLEX 404 Oral Liquid
Sponsor:   BioLite, Inc.
Not yet recruiting

Wed, 26 Oct 2016 12:00:00 EDT

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Biological: PF-06747143;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Azacitidine;   Drug: Decitabine
Sponsor:   Pfizer
Terminated

Thu, 03 Nov 2016 12:00:00 EDT

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: decitabine;   Drug: selinexor;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsors:   Bhavana Bhatnagar;   Karyopharm Therapeutics Inc
Completed

Fri, 21 Mar 2014 12:00:00 EDT

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Condition:   Leukemia, Acute Myeloid (AML)
Interventions:   Drug: gilteritinib;   Drug: LoDAC (Low Dose Cytarabine);   Drug: Azacitidine;   Drug: MEC (Mitoxantrone, Etoposide, Cytarabine);   Drug: FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)
Sponsor:   Astellas Pharma Global Development, Inc.
Active, not recruiting

Tue, 21 Apr 2015 12:00:00 EDT

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Oral CC - 486;   Drug: Romidepsin;   Drug: MK - 3475
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Merck Sharp & Dohme Corp.;   Celgene Corporation
Active, not recruiting

Thu, 30 Jul 2015 12:00:00 EDT

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes

Conditions:   Leukemia;   Myelodysplastic Syndromes
Intervention:   Drug: Azacitadine and Hematopoietic Growth Factors
Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
Terminated

Fri, 10 Nov 2006 12:00:00 EST

Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Secondary Acute Myeloid Leukemia;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: vorinostat;   Drug: decitabine
Sponsor:   National Cancer Institute (NCI)
Completed

Wed, 11 Jan 2006 12:00:00 EST

Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults With Acute Myeloid Leukemia

Conditions:   Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine;   Drug: Decitabine;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Azacitidine;   Drug: Venetoclax;   Drug: glasdegib
Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
Recruiting

Fri, 21 Jul 2017 12:00:00 EDT

Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)

Conditions:   Myeloid Leukemia;   Myelodysplastic Syndrome
Intervention:   Drug: 5-Azacytidin
Sponsor:   Technische Universität Dresden
Completed

Wed, 17 Jan 2007 12:00:00 EST

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

Condition:   Relapsed Or Refractory Multiple Myeloma
Intervention:   Drug: thymoglobulin
Sponsors:   Washington University School of Medicine;   Genzyme, a Sanofi Company
Completed

Wed, 17 Oct 2007 12:00:00 EDT

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Conditions:   Urinary Bladder Neoplasms;   Carcinoma, Transitional Cell;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Pancreatic Ductal;   Tumor Virus Infections
Interventions:   Drug: CC-486;   Drug: Carboplatin;   Drug: ABI-007
Sponsor:   Celgene
Completed

Wed, 23 Nov 2011 12:00:00 EST

Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.

Condition:   Refractory Acute Myeloid Leukemia
Intervention:   Drug: Aza-Ven-allo-HSCT
Sponsor:   Shanghai Jiao Tong University School of Medicine
Recruiting

Thu, 27 May 2021 12:00:00 EDT

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Etoposide;   Combination Product: ITMHA;   Drug: Idarubicin;   Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Erwinia asparaginase;   Drug: Sorafenib;   Drug: G-CSF;   Drug: Dexrazoxane;   Biological: Stem Cell Transplant
Sponsor:   St. Jude Children's Research Hospital
Recruiting

Tue, 23 May 2017 12:00:00 EDT

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: decitabine;   Biological: natural killer cell therapy;   Biological: aldesleukin;   Other: laboratory biomarker analysis
Sponsor:   Sumithira Vasu
Completed

Mon, 15 Dec 2014 12:00:00 EST

Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

Condition:   AML
Intervention:   Biological: APVO436
Sponsor:   Aptevo Therapeutics
Withdrawn

Thu, 22 Jul 2021 12:00:00 EDT

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Conditions:   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions:   Drug: decitabine;   Biological: NY-ESO-1 peptide vaccine;   Drug: pegylated liposomal doxorubicin hydrochloride;   Biological: sargramostim;   Biological: incomplete Freund's adjuvant;   Other: immunohistochemistry staining method;   Other: liquid chromatography;   Other: mass spectrometry;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis;   Genetic: DNA methylation analysis;   Other: enzyme-linked immunosorbent assay
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Eisai Inc.
Completed

Mon, 27 Aug 2012 12:00:00 EDT

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: HDAC inhibitor AR-42;   Drug: decitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsor:   Alison Walker
Completed

Tue, 26 Feb 2013 12:00:00 EST

A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

Condition:   Diffuse Large B Cell Lymphoma
Intervention:   Drug: Decitabine
Sponsor:   Mingzhi Zhang
Unknown status

Fri, 06 Jul 2018 12:00:00 EDT

A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma

Condition:   T-lymphoblastic Lymphoma
Interventions:   Combination Product: CODOX-M/IVAC;   Drug: Decitabine
Sponsor:   Mingzhi Zhang
Unknown status

Fri, 15 Jun 2018 12:00:00 EDT

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia, Relapsed, Adult
Interventions:   Drug: Decitabine;   Procedure: Bone marrow biopsy/aspirate;   Procedure: Peripheral blood draw;   Procedure: Skin biopsy;   Procedure: Buccal swab
Sponsors:   Washington University School of Medicine;   Janssen Pharmaceuticals;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Active, not recruiting

Fri, 24 Feb 2017 12:00:00 EST

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Condition:   Diffuse Large B-Cell Lymphoma
Interventions:   Biological: Avelumab;   Biological: Utomilumab;   Biological: Rituximab;   Other: Azacitidine;   Drug: Bendamustine;   Drug: Gemcitabine;   Drug: Oxaliplatin
Sponsors:   Pfizer;   EMD Serono
Terminated

Tue, 01 Nov 2016 12:00:00 EDT

Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy

Conditions:   Acute Myeloid Leukemia, in Relapsed or Refractory;   Acute Myeloid Leukemia, Elderly, Unfit;   Acute Myeloid Leukemia With Positive Minimal Residual Disease
Intervention:   Drug: Tislelizumab
Sponsor:   Chinese PLA General Hospital
Recruiting

Wed, 09 Sep 2020 12:00:00 EDT

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Philadelphia Chromosome Negative Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions:   Drug: decitabine;   Drug: vorinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 27 Jul 2006 12:00:00 EDT

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: SGI-110 (guadecitabine);   Drug: Treatment Choice
Sponsor:   Astex Pharmaceuticals, Inc.
Completed

Wed, 28 Jan 2015 12:00:00 EST

Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Conditions:   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions:   Drug: decitabine;   Drug: valproic acid;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Wed, 04 May 2005 12:00:00 EDT

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation

Condition:   Recurrent Adult Acute Myeloid Leukemia
Intervention:   Drug: Deciatbine(DAC)
Sponsors:   Chinese PLA General Hospital;   Navy General Hospital, Beijing
Unknown status

Tue, 01 Jan 2013 12:00:00 EST

Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer

Conditions:   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions:   Drug: decitabine;   Drug: valproic acid;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 11 Jun 2004 12:00:00 EDT

Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: decitabine;   Drug: valproic acid;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Wed, 10 Mar 2004 12:00:00 EST

Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: decitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: high performance liquid chromatography;   Genetic: microarray analysis;   Genetic: RNA analysis;   Other: mass spectrometry;   Genetic: DNA methylation analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry
Sponsor:   National Cancer Institute (NCI)
Completed

Wed, 27 Jun 2007 12:00:00 EDT

Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: bortezomib;   Drug: decitabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 23 Jun 2008 12:00:00 EDT

Clofarabine in High Risk Myelodysplastic Syndrome (MDS)

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: Clofarabine
Sponsors:   Groupe Francophone des Myelodysplasies;   Genzyme, a Sanofi Company
Completed

Fri, 05 Feb 2010 12:00:00 EST

GFM-Acadesine: A Phase I-II Trial of Acadesine

Condition:   SMD
Interventions:   Drug: ACADESINE 140mg/kg/d;   Drug: ACADESINE 210mg/kg/d;   Drug: ACADESINE 315mg/kg/d
Sponsors:   Groupe Francophone des Myelodysplasies;   Advancell - Advanced In Vitro Cell Technologies, S.A.
Terminated

Tue, 19 Mar 2013 12:00:00 EDT

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

Conditions:   Myelodysplastic Syndromes;   MDS;   RAEB;   Chronic Myelomonocytic Leukemia
Intervention:   Drug: ON 01910.Na
Sponsors:   Onconova Therapeutics, Inc.;   The Leukemia and Lymphoma Society
Completed

Tue, 16 Nov 2010 12:00:00 EST

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Thrombocytopenia
Interventions:   Other: flow cytometry;   Other: DNA methylation analysis;   Other: cytogenetic analysis;   Drug: decitabine;   Genetic: microarray analysis;   Genetic: gene expression analysis;   Other: pharmacological study;   Genetic: polymorphism analysis
Sponsor:   Case Comprehensive Cancer Center
Completed

Tue, 20 Jul 2010 12:00:00 EDT

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Intervention:   Drug: decitabine
Sponsor:   Washington University School of Medicine
Completed

Tue, 18 Sep 2012 12:00:00 EDT

Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Condition:   Leukemia
Interventions:   Drug: Eltrombopag;   Drug: Hypomethylating Agent (HMA)
Sponsors:   M.D. Anderson Cancer Center;   GlaxoSmithKline;   Novartis
Completed

Tue, 09 Jul 2013 12:00:00 EDT

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation
Interventions:   Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Poly ICLC
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Completed

Wed, 17 Apr 2013 12:00:00 EDT

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults;   AML (Adult) With 11q23 (MLL) Abnormalities;   AML (Adult) With Del (5q);   AML (Adult) With Inv (16) (p13; q22);   AML (Adult) With t (16;16) (p13; q22);   AML (Adult) With t (8; 21) (q22; q22);   Secondary AML (Adult);   Untreated AML (Adult)
Interventions:   Drug: Decitabine;   Drug: Midostaurin
Sponsor:   David Iberri
Terminated

Fri, 03 May 2013 12:00:00 EDT

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS

Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts
Interventions:   Drug: decitabine;   Drug: idarubicin;   Drug: cytarabine
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Terminated

Wed, 30 May 2012 12:00:00 EDT

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: cytarabine;   Drug: omacetaxine mepesuccinate;   Drug: decitabine;   Other: laboratory biomarker analysis
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Teva Pharmaceutical Industries, Ltd.
Terminated

Tue, 07 Jan 2014 12:00:00 EST

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Condition:   Previously Untreated Acute Myeloid Leukemia
Interventions:   Biological: Samalizumab (BAML-16-001-S1);   Biological: BI 836858 (BAML-16-001-S2);   Other: Laboratory Biomarker Analysis;   Drug: Daunorubicin (BAML-16-001-S1);   Drug: Cytarabine (BAML-16-001-S1);   Drug: Azacitidine (BAML-16-001-S2);   Drug: AG-221 (BAML-16-001-S3);   Drug: Azacitidine (BAML-16-001-S3);   Drug: Entospletinib (BAML-16-001-S4);   Drug: Azacitidine (BAML-16-001-S4);   Drug: Entospletinib (BAML-16-001-S5);   Drug: Decitabine (BAML-16-001-S5);   Drug: Entospletinib (BAML-16-001-S6);   Drug: Daunorubicin (BAML-16-001-S6);   Drug: Cytarabine (BAML-16-001-S6);   Drug: Pevonedistat (BAML-16-001-S9);   Drug: Azacitidine (BAML-16-001-S9);   Drug: AG-120 (BAML-16-001-S16);   Drug: Azacitidine (BAML-16-001-S16);   Drug: Gilteritinib (BAML-16-001-S8 Group 1);   Drug: Decitabine (BAML-16-001-S8 Group 1);   Drug: AZD5153 (BAML-16-001-S10);   Drug: Venetoclax (BAML-16-001-S10);   Drug: TP-0903 (BAML-16-001-S14);   Drug: Decitabine (BAML-16-001-S14);   Drug: Decitabine (BAML-16-001-S8 Group 2);   Drug: Venetoclax (BAML-16-001-S8 Group 2);   Drug: AZD5991 (BAML-16-001-S18);   Drug: Azacitidine (BAML-16-001-S18)
Sponsor:   Beat AML, LLC
Recruiting

Mon, 09 Jan 2017 12:00:00 EST

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Blasts 30 Percent or Less of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Refractory Anemia
Interventions:   Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Poly ICLC
Sponsors:   Roswell Park Cancer Institute;   Celldex Therapeutics
Completed

Sat, 02 Dec 2017 12:00:00 EST

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Conditions:   Myelodysplastic Syndrome;   Acute Myelogenous Leukemia
Interventions:   Drug: Decitabine;   Drug: Valproic Acid
Sponsors:   M.D. Anderson Cancer Center;   Eisai Inc.
Completed

Thu, 21 Dec 2006 12:00:00 EST

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Conditions:   Solid Tumors;   Advanced Malignancies;   Metastatic Cancer
Interventions:   Drug: INCB052793;   Drug: gemcitabine;   Drug: nab-paclitaxel;   Drug: dexamethasone;   Drug: Carfilzomib;   Drug: bortezomib;   Drug: lenalidomide;   Drug: azacitidine;   Drug: pomalidomide;   Drug: INCB050465;   Drug: INCB039110
Sponsor:   Incyte Corporation
Terminated

Thu, 16 Oct 2014 12:00:00 EDT

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Camrelizumab(SHR-1210);   Drug: Decitabine
Sponsor:   Shanghai Jiao Tong University School of Medicine
Not yet recruiting

Mon, 20 Apr 2020 12:00:00 EDT

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Conditions:   Paraganglioma;   Gastrointestinal Stromal Tumors;   Carcinoma, Renal Cell;   Renal Neoplasms;   Pheochromocytoma
Intervention:   Drug: SGI-110 (guadecitabine)
Sponsor:   National Cancer Institute (NCI)
Terminated

Wed, 24 May 2017 12:00:00 EDT

Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial

Condition:   COVID-19
Interventions:   Drug: Decitabine;   Other: Placebo Saline
Sponsor:   Johns Hopkins University
Recruiting

Wed, 22 Jul 2020 12:00:00 EDT

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

Conditions:   Acute Myeloid Leukemia;   High Risk Acute Myeloid Leukemia;   High Risk Myelodysplastic Syndrome;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome
Interventions:   Biological: Donor Lymphocytes;   Drug: Guadecitabine;   Other: Laboratory Biomarker Analysis
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Wed, 17 Feb 2016 12:00:00 EST

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

Conditions:   Germ Cell Tumor;   Testis Cancer;   Testicular Cancer
Intervention:   Drug: Guadecitabine (SGI-110)
Sponsor:   Nasser Hanna
Completed

Wed, 29 Apr 2015 12:00:00 EDT

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

Conditions:   Recurrent Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer
Interventions:   Drug: Decitabine;   Radiation: Iodine I 131;   Biological: Recombinant thyrotropin alfa;   Radiation: Fludeoxyglucose F 18;   Procedure: Positron emission tomography
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 11 Jun 2004 12:00:00 EDT

Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes

Condition:   High Risk Myelodysplastic Syndrome
Intervention:   Drug: Guadecitabine
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting

Tue, 06 May 2014 12:00:00 EDT

Prospective Study of Patients With Thrombocytopenia Following HSCT

Conditions:   Thrombocytopenia;   Hematologic Diseases
Interventions:   Drug: Decitabine;   Drug: rhTPO;   Other: Conventional Treatment
Sponsors:   The First Affiliated Hospital of Soochow University;   Peking University People's Hospital;   Nanfang Hospital of Southern Medical University;   Ruijin Hospital;   Wuhan Union Hospital, China;   Qilu Hospital of Shandong University;   Children's Hospital Of Soochow University;   Fujian Medical University Union Hospital;   Hebei Yanda Ludaopei Hospital
Completed

Wed, 01 Jul 2015 12:00:00 EDT

SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Conditions:   MDS;   CMML;   AML
Intervention:   Drug: SGI-110
Sponsor:   Astex Pharmaceuticals, Inc.
Completed

Thu, 16 Dec 2010 12:00:00 EST

Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients

Condition:   Acute Myelogenous Leukemia
Intervention:   Drug: Decitabine
Sponsor:   University of Rochester
Active, not recruiting

Thu, 10 Apr 2014 12:00:00 EDT

Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Conditions:   Acute Myeloid Leukemia;   Essential Thrombocythemia;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions:   Drug: Decitabine;   Drug: Ruxolitinib;   Drug: Fedratinib;   Other: Questionnaire Administration
Sponsor:   University of Washington
Recruiting

Mon, 24 Feb 2020 12:00:00 EST

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Conditions:   Acute Myeloid Leukemia;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: STAT Inhibitor OPB-111077;   Drug: Decitabine;   Drug: Venetoclax;   Other: Laboratory Biomarker Analysis
Sponsors:   Sidney Kimmel Cancer Center at Thomas Jefferson University;   Otsuka America Pharmaceutical
Recruiting

Fri, 24 Feb 2017 12:00:00 EST

Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: tosedostat;   Drug: cytarabine;   Drug: decitabine
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Completed

Fri, 30 Mar 2012 12:00:00 EDT

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Condition:   Myeloid Malignancies
Interventions:   Biological: Magrolimab;   Drug: Azacitidine;   Drug: Venetoclax;   Drug: Mitoxantrone;   Drug: Etoposide;   Drug: Cytarabine;   Drug: CC-486
Sponsor:   Gilead Sciences
Recruiting

Wed, 03 Mar 2021 12:00:00 EST

Decitabine in Treating Patients With Myelodysplastic Syndrome

Conditions:   Leukemia;   Myelodysplastic Syndromes
Intervention:   Drug: decitabine
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
Completed

Fri, 12 Mar 2004 12:00:00 EST

Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease

Condition:   Sickle Cell Disease
Interventions:   Drug: Oral Decitabine and Tetrahydrouridine;   Drug: Placebo
Sponsors:   Yogen Saunthararajah;   University of Illinois at Chicago
Completed

Fri, 14 Sep 2012 12:00:00 EDT

Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)

Conditions:   Liver Metastasis;   Colorectal Cancer
Intervention:   Drug: Decitabine
Sponsors:   Universitair Ziekenhuis Brussel;   Janssen, LP
Completed

Fri, 12 Dec 2014 12:00:00 EST

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Drug: decitabine
Sponsors:   California Cancer Consortium;   National Cancer Institute (NCI)
Completed

Fri, 03 Sep 2004 12:00:00 EDT

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: Decitabine;   Drug: Valproic acid
Sponsors:   M.D. Anderson Cancer Center;   Eisai Inc.
Completed

Wed, 31 Dec 2003 12:00:00 EST

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Conditions:   Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia
Intervention:   Drug: Decitabine
Sponsors:   M.D. Anderson Cancer Center;   Eisai Inc.
Completed

Thu, 28 Aug 2003 12:00:00 EDT

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions:   Drug: decitabine;   Drug: romidepsin
Sponsor:   National Cancer Institute (NCI)
Completed

Tue, 14 Jun 2005 12:00:00 EDT

Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: Asacol;   Drug: Lialda
Sponsor:   Warner Chilcott
Completed

Fri, 12 Sep 2008 12:00:00 EDT

Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: carboplatin;   Drug: decitabine
Sponsor:   Cancer Research UK
Terminated

Mon, 08 Sep 2008 12:00:00 EDT

Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma

Conditions:   Neuroblastoma;   Ewings Sarcoma;   Osteogenic Sarcoma;   Rhabdomyosarcoma;   Synovial Sarcoma
Intervention:   Biological: Autologous dendritic cell vaccine with adjuvant
Sponsors:   University of Louisville;   Solving Kids' Cancer
Completed

Tue, 16 Nov 2010 12:00:00 EST

Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome

Conditions:   Myelodysplastic Syndromes;   Dendritic Cell;   Hypomethylating Agents;   Immunotherapy
Intervention:   Biological: DC vaccine
Sponsor:   Affiliated Hospital to Academy of Military Medical Sciences
Recruiting

Wed, 11 Aug 2021 12:00:00 EDT

Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML

Conditions:   Refractory Acute Myeloid Leukemia;   Relapsed Acute Erythroid Leukemia;   Salvage Treatment;   HVA Regimen
Intervention:   Combination Product: HVA Regimens as Salvage Treatment
Sponsors:   Nanfang Hospital of Southern Medical University;   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;   Guangzhou First People's Hospital;   Peking University People's Hospital;   Southern Medical University, China;   Third Affiliated Hospital, Sun Yat-Sen University
Enrolling by invitation

Tue, 09 Jun 2020 12:00:00 EDT

Individualized Induction Therapy for Non-elderly AML Patients With Adverse Risk Features

Condition:   Acute Myeloid Leukemia, Adult
Intervention:   Drug: venetoclax combined with decitabine
Sponsor:   The First Affiliated Hospital of Soochow University
Not yet recruiting

Fri, 12 Feb 2021 12:00:00 EST

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Condition:   Solid Tumors
Interventions:   Drug: INCB057643;   Drug: Gemcitabine;   Drug: Paclitaxel;   Drug: Rucaparib;   Drug: Abiraterone;   Drug: Ruxolitinib;   Drug: Azacitidine
Sponsor:   Incyte Corporation
Terminated

Thu, 17 Mar 2016 12:00:00 EDT

NK Cell Therapy Recurrent/Refractory Elderly AML

Conditions:   AML;   Recurrent;   Refractory;   Elderly
Intervention:   Biological: Allogeneic NK cell regimen group
Sponsor:   The Second Hospital of Shandong University
Not yet recruiting

Thu, 22 Oct 2020 12:00:00 EDT

Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES

Condition:   Myelodysplastic Syndrome
Intervention:  
Sponsor:   Fondazione Amelia Scorza Onlus
Unknown status

Tue, 08 Feb 2011 12:00:00 EST

LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Interventions:   Drug: LBH589;   Drug: Decitabine
Sponsor:   Washington University School of Medicine
Completed

Fri, 06 Jun 2008 12:00:00 EDT

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

Conditions:   Colorectal Adenocarcinoma;   CpG Island Methylator Phenotype;   Metastatic Microsatellite Stable Colorectal Carcinoma;   Refractory Colorectal Carcinoma;   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8
Interventions:   Drug: Guadecitabine;   Biological: Nivolumab
Sponsors:   University of Southern California;   National Cancer Institute (NCI);   Bristol-Myers Squibb;   Astex Pharmaceuticals, Inc.
Withdrawn

Thu, 05 Jul 2018 12:00:00 EDT

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Drug: Guadecitabine;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
Sponsors:   Northwestern University;   Merck Sharp & Dohme Corp.;   Astex Pharmaceuticals, Inc.;   National Cancer Institute (NCI)
Active, not recruiting

Thu, 15 Sep 2016 12:00:00 EDT

A Safety Study of SGN-CD33A in AML Patients

Conditions:   Acute Myelogenous Leukemia;   Acute Myeloid Leukemia;   Acute Promyelocytic Leukemia
Interventions:   Drug: HMA;   Drug: SGN-CD33A
Sponsor:   Seagen Inc.
Completed

Thu, 18 Jul 2013 12:00:00 EDT

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: selinexor (KPT-330)
Sponsors:   Memorial Sloan Kettering Cancer Center;   M.D. Anderson Cancer Center;   Columbia University;   Karyopharm Therapeutics Inc
Completed

Fri, 29 Aug 2014 12:00:00 EDT

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Conditions:   Angioimmunoblastic T-cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Follicular T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma;   Nodal Peripheral T-Cell Lymphoma With TFH Phenotype;   Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Etoposide;   Drug: Duvelisib;   Drug: Oral azacitidine
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Recruiting

Wed, 17 Mar 2021 12:00:00 EDT

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: MBG453;   Drug: Placebo;   Drug: Hypomethylating agents
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting

Mon, 13 May 2019 12:00:00 EDT

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: alemtuzumab;   Drug: arsenic trioxide;   Drug: azacitidine;   Drug: busulfan;   Drug: clofarabine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: fludarabine phosphate;   Drug: gemtuzumab ozogamicin;   Drug: melphalan;   Drug: tipifarnib;   Genetic: DNA methylation analysis;   Genetic: cytogenetic analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunologic technique;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Sponsor:   The University of New South Wales
Completed

Fri, 30 Mar 2007 12:00:00 EDT

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Conditions:   Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Non-Hodgkin's Lymphoma;   Neuroblastoma
Interventions:   Drug: chemotherapy;   Drug: venetoclax
Sponsors:   AbbVie;   Roche-Genentech
Recruiting

Wed, 02 Aug 2017 12:00:00 EDT

DCHA as Postremission Therapy for AML With t(8;21)

Condition:   Chemotherapy
Intervention:   Drug: Chemotherapy
Sponsor:   Chinese PLA General Hospital
Unknown status

Mon, 05 Mar 2018 12:00:00 EST

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

Conditions:   Urothelial Carcinoma;   Bladder Cancer;   Urinary Bladder Neoplasms
Interventions:   Drug: 75 approved agents;   Other: COXEN
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 02 Jun 2016 12:00:00 EDT

A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Procedure: Hematopoietic stem cell transplantation;   Drug: Best chemotherapy treatment
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting

Tue, 30 Mar 2021 12:00:00 EDT

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: clofarabine;   Drug: daunorubicin hydrochloride;   Other: clinical observation;   Drug: cytarabine;   Drug: decitabine;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Active, not recruiting

Wed, 12 Mar 2014 12:00:00 EDT

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   AML, Adult;   CLL;   CLL, Relapsed;   CLL, Refractory
Interventions:   Drug: Pitavastatin;   Drug: Venetoclax
Sponsors:   University of California, Irvine;   United States Department of Defense
Recruiting

Thu, 13 Aug 2020 12:00:00 EDT

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: guadecitabine;   Drug: Treatment Choice (TC)
Sponsor:   Astex Pharmaceuticals, Inc.
Completed

Fri, 30 Sep 2016 12:00:00 EDT

Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Condition:   Acute Myeloid Leukemia (AML)
Intervention:  
Sponsor:   Acute Leukemia French Association
Not yet recruiting

Tue, 02 Mar 2021 12:00:00 EST

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Leukemia, Acute Myeloid;   Myeloid Leukemia, Acute;   Leukemia, Myeloid, Acute;   Acute Myelogenous Leukemia;   Leukemia, Acute Myelogenous;   Myelogenous Leukemia, Acute;   AML;   Bone Marrow Transplant
Interventions:   Drug: Iomab-B;   Drug: Conventional Care;   Procedure: HCT
Sponsor:   Actinium Pharmaceuticals
Recruiting

Wed, 27 Jan 2016 12:00:00 EST

Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: decitabine
Sponsors:   Indiana University;   Eisai Inc.
Completed

Wed, 23 May 2007 12:00:00 EDT

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Conditions:   Locally Advanced Unresectable Primary Central Chondrosarcoma;   Metastatic Primary Central Chondrosarcoma;   Unresectable Primary Central Chondrosarcoma
Interventions:   Drug: Belinostat;   Procedure: Biopsy;   Procedure: Computed Tomography;   Drug: Decitabine and Cedazuridine;   Drug: Guadecitabine;   Procedure: Magnetic Resonance Imaging
Sponsor:   National Cancer Institute (NCI)
Recruiting

Fri, 10 Apr 2020 12:00:00 EDT

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Conditions:   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Interventions:   Drug: Atezolizumab;   Drug: Guadecitabine
Sponsors:   University of Southern California;   National Cancer Institute (NCI);   Van Andel Research Institute
Active, not recruiting

Mon, 17 Oct 2016 12:00:00 EDT

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1

Conditions:   Melanoma;   Non Small Cell Lung Cancer
Interventions:   Drug: Ipilimumab plus nivolumab plus guadecitabine;   Drug: Ipilimumab plus nivolumab
Sponsors:   Italian Network for Tumor Biotherapy Foundation;   Astex Pharmaceuticals, Inc.;   Bristol-Myers Squibb
Not yet recruiting

Fri, 31 Jan 2020 12:00:00 EST

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

Condition:   Previously Treated Metastatic Colorectal Cancer
Interventions:   Drug: SGI-110 Dose Escalation;   Drug: Regorafenib;   Drug: TAS-102;   Drug: SGI-110;   Drug: Irinotecan
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Van Andel Research Institute;   Astex Pharmaceuticals, Inc.
Completed

Thu, 11 Jul 2013 12:00:00 EDT

Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

Conditions:   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: decitabine;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 12 Jan 2004 12:00:00 EST

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia
Interventions:   Drug: JNJ-74856665;   Drug: AZA;   Drug: VEN
Sponsor:   Janssen Research & Development, LLC
Recruiting

Fri, 30 Oct 2020 12:00:00 EDT

Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly

Condition:   Acute Myeloid Leukemia
Intervention:   Other: Transfusion
Sponsor:   Hospices Civils de Lyon
Completed

Wed, 27 Jul 2016 12:00:00 EDT

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Conditions:   Leukemia, Acute;   MDS
Interventions:   Procedure: Bone Marrow or Peripheral Blood Graft (BMT);   Other: Cancer-directed Therapy or Best Supportive Care;   Diagnostic Test: Frailty Assessment
Sponsor:   Abramson Cancer Center of the University of Pennsylvania
Recruiting

Fri, 21 Sep 2018 12:00:00 EDT

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: decitabine;   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: filgrastim;   Radiation: total-body irradiation;   Procedure: allogeneic bone marrow transplantation;   Other: laboratory biomarker analysis
Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
Completed

Mon, 15 Oct 2012 12:00:00 EDT

Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction

Condition:   Cocaine Addiction
Interventions:   Drug: N-Acetylcystein;   Drug: Placebo
Sponsors:   Psychiatric University Hospital, Zurich;   Zurich Center for Integrative Human Physiology;   Swiss Federal Institute of Technology;   Max-Planck-Institut Tübingen
Completed

Thu, 10 Dec 2015 12:00:00 EST

An European Platform for Translational Research in Myelodysplastic Syndromes

Condition:   Myelodysplastic Syndromes
Intervention:  
Sponsor:   Istituto Clinico Humanitas
Recruiting

Fri, 22 Nov 2019 12:00:00 EST

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Condition:   Peripheral T-cell Lymphoma
Interventions:   Drug: Decitabine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
Sponsor:   Southwest Hospital, China
Unknown status

Tue, 12 Jun 2018 12:00:00 EDT

Decitabine in Treating Patients With Myelofibrosis

Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions:   Drug: Decitabine;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Tue, 09 Nov 2004 12:00:00 EST

Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Condition:   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Cladribine;   Drug: Guadecitabine;   Drug: Idarubicin
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Completed

Wed, 26 Mar 2014 12:00:00 EDT

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

Conditions:   Myelodysplastic Syndrome;   MDS;   Refractory Anemia With Excess Blasts;   RAEB
Interventions:   Drug: rigosertib;   Drug: Any approved or standard-of-care therapy;   Drug: best supportive care (BSC)
Sponsor:   Onconova Therapeutics, Inc.
Active, not recruiting

Tue, 29 Sep 2015 12:00:00 EDT

Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: ON 01910.Na
Sponsor:   Onconova Therapeutics, Inc.
Completed

Thu, 21 May 2009 12:00:00 EDT

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Conditions:   Non-Hodgkin Lymphoma (NHL);   Multiple Myeloma (MM);   Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL);   Acute Myeloid Leukemia (AML)
Interventions:   Drug: azacitadine;   Drug: venetoclax;   Drug: rituximab / IDEC-C2B8
Sponsors:   AbbVie;   Genentech, Inc.
Completed

Thu, 16 Oct 2014 12:00:00 EDT

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: ASLAN003
Sponsor:   Aslan Pharmaceuticals
Completed

Thu, 01 Mar 2018 12:00:00 EST

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Conditions:   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Pacritinib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsors:   Bhavana Bhatnagar;   CTI BioPharma
Completed

Tue, 23 Dec 2014 12:00:00 EST

Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia

Conditions:   Chronic Myelomonocytic Leukemia;   Chronic Myelomonocytic Leukemia-1;   Chronic Myelomonocytic Leukemia-2;   Myelodysplastic/Myeloproliferative Neoplasm
Interventions:   Drug: Decitabine;   Biological: Tagraxofusp-erzs
Sponsor:   M.D. Anderson Cancer Center
Not yet recruiting

Thu, 09 Sep 2021 12:00:00 EDT

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Conditions:   Recurrent Leukemia;   Refractory Leukemia
Interventions:   Drug: Decitabine;   Drug: Tegavivint
Sponsor:   M.D. Anderson Cancer Center
Not yet recruiting

Wed, 05 May 2021 12:00:00 EDT

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Chronic Myelomonocytic Leukemia;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Recurrent Acute Biphenotypic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent Mixed Phenotype Acute Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm;   Refractory Chronic Myelomonocytic Leukemia;   Refractory Mixed Phenotype Acute Leukemia
Interventions:   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Fri, 19 Jan 2018 12:00:00 EST

KRT-232 (AMG-232) and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: Decitabine;   Drug: MDM2 Inhibitor KRT-232
Sponsor:   National Cancer Institute (NCI)
Recruiting

Fri, 03 Feb 2017 12:00:00 EST

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Conditions:   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome
Interventions:   Drug: Decitabine;   Biological: Ipilimumab
Sponsor:   National Cancer Institute (NCI)
Recruiting

Wed, 07 Sep 2016 12:00:00 EDT

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Pevonedistat;   Other: Pharmacological Study
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Active, not recruiting

Wed, 04 Jan 2017 12:00:00 EST

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

Conditions:   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Gene Mutations;   FLT3 Tyrosine Kinase Domain Point Mutation;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Terminated

Fri, 18 Dec 2015 12:00:00 EST

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
Interventions:   Procedure: Peripheral blood draw;   Procedure: Bone marrow aspirate;   Procedure: Buccal swab
Sponsors:   Washington University School of Medicine;   Notable Labs
Recruiting

Mon, 10 Feb 2020 12:00:00 EST

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

Conditions:   Chronic Myelomonocytic Leukemia-2;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Completed

Wed, 23 Apr 2014 12:00:00 EDT

Registry on Hypomethylating Agents in Myeloid Neoplasms

Conditions:   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
Intervention:   Other: non interventional
Sponsor:   Arbeitsgemeinschaft medikamentoese Tumortherapie
Active, not recruiting

Thu, 10 May 2012 12:00:00 EDT

The Effects of Neuraminidase Inhibitor Oseltamivir in Patients With Chronic Heart Failure

Condition:   Heart Failure
Intervention:   Drug: Oseltamivir
Sponsor:   Tongji Hospital
Recruiting

Tue, 17 Aug 2021 12:00:00 EDT

An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

Condition:   GNE Myopathy
Intervention:   Drug: ManNAc
Sponsors:   National Human Genome Research Institute (NHGRI);   National Center for Advancing Translational Science (NCATS)
Completed

Tue, 27 Jan 2015 12:00:00 EST

Decitabine and Talazoparib in Untreated AML and R/R AML

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Decitabine;   Drug: talazoparib
Sponsors:   University of Maryland, Baltimore;   Pfizer;   Van Andel Research Institute
Active, not recruiting

Thu, 25 Aug 2016 12:00:00 EDT

Outcomes of Patients After Allo-HSCT With Decitabine and NAC

Conditions:   Engraft Failure;   Relapse;   GVHD
Interventions:   Drug: decitabine;   Drug: Acetylcysteine;   Drug: Semustine;   Drug: Cytarabine;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporin A;   Drug: Anti-thymocyte globulin;   Drug: Mycophenolate
Sponsor:   The First Affiliated Hospital of Soochow University
Not yet recruiting

Wed, 30 Jun 2021 12:00:00 EDT

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Drug: Atezolizumab;   Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Guadecitabine;   Other: Laboratory Biomarker Analysis;   Drug: Poly ICLC
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Sun, 02 Jul 2017 12:00:00 EDT

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Decitabine;   Biological: Nivolumab;   Drug: Venetoclax
Sponsor:   National Cancer Institute (NCI)
Suspended

Thu, 20 Feb 2020 12:00:00 EST

Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Conditions:   Acute Myeloid Leukemia;   High Risk Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory High Risk Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
Interventions:   Drug: Decitabine;   Biological: Pembrolizumab
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Recruiting

Fri, 31 May 2019 12:00:00 EDT

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Myeloid Leukemia;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions:   Drug: Decitabine;   Drug: Ponatinib;   Drug: Venetoclax
Sponsor:   M.D. Anderson Cancer Center
Recruiting

Thu, 05 Dec 2019 12:00:00 EST

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma in the Soft Tissue;   Prostate Carcinoma Metastatic in the Bone;   PSA Level Greater Than or Equal to Two;   PSA Progression;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
Interventions:   Drug: Decitabine;   Drug: Enzalutamide
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Withdrawn

Wed, 17 Oct 2018 12:00:00 EDT

Epigenetic Reprogramming in Relapse AML

Condition:   Leukemia, Acute Myeloid
Interventions:   Drug: Decitabine;   Drug: Vorinostat;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Filgrastim;   Drug: Sorafenib
Sponsors:   Michael Burke;   Children's Hospitals and Clinics of Minnesota
Terminated

Thu, 09 Apr 2015 12:00:00 EDT

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Decitabine;   Drug: Quizartinib;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Fri, 07 Sep 2018 12:00:00 EDT

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Conditions:   Blasts More Than 20 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 20 Percent of Peripheral Blood White Cells;   Myelodysplastic/Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Ruxolitinib Phosphate
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Completed

Mon, 06 Oct 2014 12:00:00 EDT

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

Conditions:   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Alvocidib Hydrochloride;   Drug: Decitabine;   Drug: Venetoclax
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Withdrawn

Thu, 30 Jul 2020 12:00:00 EDT

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
Interventions:   Drug: Bortezomib;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Sorafenib Tosylate
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Thu, 23 May 2013 12:00:00 EDT

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Decitabine;   Biological: Genetically Engineered NY-ESO-1-specific T Lymphocytes;   Other: Laboratory Biomarker Analysis
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Active, not recruiting

Wed, 11 Jan 2017 12:00:00 EST

Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Therapy-Related Acute Myeloid Leukemia
Interventions:   Drug: Bortezomib;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Mon, 22 Aug 2011 12:00:00 EDT

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions:   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vorinostat
Sponsor:   National Cancer Institute (NCI)
Completed

Wed, 26 May 2010 12:00:00 EDT

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Conditions:   Recurrent Acute Leukemia of Ambiguous Lineage;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Acute Leukemia of Ambiguous Lineage
Interventions:   Other: Chemosensitivity Assay;   Other: Cytology Specimen Collection Procedure;   Genetic: Gene Expression Analysis;   Genetic: Genetic Variation Analysis;   Drug: In Vitro Sensitivity-Directed Chemotherapy
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Active, not recruiting

Wed, 16 Sep 2015 12:00:00 EDT

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Adult Acute Basophilic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Mon, 25 Jun 2012 12:00:00 EDT

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions:   Drug: Decitabine;   Drug: Gemtuzumab Ozogamicin
Sponsor:   M.D. Anderson Cancer Center
Completed

Fri, 28 Aug 2009 12:00:00 EDT

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Conditions:   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Decitabine;   Drug: Dexamethasone;   Drug: Palbociclib;   Drug: Sorafenib
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Thu, 27 Apr 2017 12:00:00 EDT

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Conditions:   Advanced Fallopian Tube Carcinoma;   Advanced Malignant Solid Neoplasm;   Advanced Melanoma;   Advanced Ovarian Carcinoma;   Advanced Primary Peritoneal Carcinoma;   Advanced Synovial Sarcoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Metastatic Fallopian Tube Carcinoma;   Metastatic Melanoma;   Metastatic Ovarian Carcinoma;   Metastatic Primary Peritoneal Carcinoma;   Metastatic Synovial Sarcoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Stage III Fallopian Tube Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Primary Peritoneal Cancer AJCC v8;   Stage IIIA Fallopian Tube Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Primary Peritoneal Cancer AJCC v8;   Stage IIIA1 Fallopian Tube Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Fallopian Tube Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Fallopian Tube Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Primary Peritoneal Cancer AJCC v8;   Stage IIIC Fallopian Tube Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Primary Peritoneal Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8;   Unresectable Melanoma;   Unresectable Ovarian Carcinoma;   Unresectable Synovial Sarcoma
Interventions:   Drug: Cyclophosphamide;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis;   Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Active, not recruiting

Fri, 08 Jan 2016 12:00:00 EST

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Conditions:   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine;   Drug: Decitabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Completed

Tue, 20 Nov 2012 12:00:00 EST

Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions:   Allogeneic Stem Cell Transplant Recipient;   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine;   Drug: Cytarabine Hydrochloride;   Drug: Decitabine;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Biological: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Sponsors:   Sumithira Vasu;   National Cancer Institute (NCI)
Recruiting

Tue, 07 Jan 2020 12:00:00 EST

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Conditions:   Mixed Phenotype Acute Leukemia;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory High Risk Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Decitabine;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Completed

Fri, 30 Sep 2016 12:00:00 EDT

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

Condition:   Recurrent Acute Myeloid Leukemia
Interventions:   Drug: Bosutinib Monohydrate;   Drug: Decitabine;   Drug: Enasidenib Mesylate;   Drug: Gilteritinib Fumarate;   Drug: Glasdegib Maleate;   Drug: Ivosidenib;   Drug: Venetoclax
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Not yet recruiting

Mon, 07 Dec 2020 12:00:00 EST

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions:   Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   de Novo Myelodysplastic Syndrome;   High Risk Myelodysplastic Syndrome;   Inv(16);   Myelodysplastic Syndrome With Excess Blasts;   t(16;16);   t(8;21);   Untreated Adult Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine;   Drug: Decitabine;   Biological: Filgrastim-sndz;   Drug: Fludarabine Phosphate;   Drug: Gemtuzumab Ozogamicin;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Wed, 03 Dec 2008 12:00:00 EST

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Decitabine;   Drug: Etoposide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 28 Dec 2006 12:00:00 EST